Patent Application
20250228121
The present disclosure generally relates to organic or metal coordination compounds and formulations and their various uses including as emitters, sensitizers, charge transporters, or exciton transporters in devices such as organic light emitting diodes and related electronic devices and consumer products.
Opto-electronic devices that make use of organic materials are becoming increasingly desirable for various reasons. Many of the materials used to make such devices are relatively inexpensive, so organic opto-electronic devices have the potential for cost advantages over inorganic devices. In addition, the inherent properties of organic materials, such as their flexibility, may make them well suited for particular applications such as fabrication on a flexible substrate. Examples of organic opto-electronic devices include organic light emitting diodes/devices (OLEDs), organic phototransistors, organic photovoltaic cells, and organic photodetectors. For OLEDs, the organic materials may have performance advantages over conventional materials.
OLEDs make use of thin organic films that emit light when voltage is applied across the device. OLEDs are becoming an increasingly interesting technology for use in applications such as flat panel displays, illumination, and backlighting.
One application for phosphorescent emissive molecules is a full color display. Industry standards for such a display call for pixels adapted to emit particular colors, referred to as “saturated” colors. In particular, these standards call for saturated red, green, and blue pixels. Alternatively, the OLED can be designed to emit white light. In conventional liquid crystal displays emission from a white backlight is filtered using absorption filters to produce red, green and blue emission. The same technique can also be used with OLEDs. The white OLED can be either a single emissive layer (EML) device or a stack structure. Color may be measured using CIE coordinates, which are well known to the art.
In one aspect, the present disclosure provides a compound having a Formula Ir(LA)x(LB)y(Lc)z,
In another aspect, the present disclosure provides an Ir complex having a ligand LA″ comprising a structure of Formula III;
wherein:
fused to ring H or ring G; n is 1, 2, or 3;
the dashed lines in Formula II represent a direct bond to two adjacent carbon atoms;
In another aspect, the present disclosure provides a formulation comprising a compound having a Formula Ir(LA)x(LB)y(Lc)z as described herein.
In yet another aspect, the present disclosure provides an OLED having an organic layer comprising a compound having a Formula Ir(LA)x(LB)y(Lc)z as described herein.
In yet another aspect, the present disclosure provides a consumer product comprising an OLED with an organic layer comprising a compound having a Formula Ir(LA)x(LB)y(Lc)z as described herein.
In another aspect, the present disclosure provides a formulation comprising a compound having a ligand LA″ comprising a structure of Formula III as described herein.
In yet another aspect, the present disclosure provides an OLED having an organic layer comprising a compound having a ligand LA″ comprising a structure of Formula III as described herein.
In yet another aspect, the present disclosure provides a consumer product comprising an OLED with an organic layer comprising a compound having a ligand LA″ comprising a structure of Formula III as described herein.
Unless otherwise specified, the below terms used herein are defined as follows:
As used herein, “top” means furthest away from the substrate, while “bottom” means closest to the substrate. Where a first layer is described as “disposed over” a second layer, the first layer is disposed further away from substrate. There may be other layers between the first and second layer, unless it is specified that the first layer is “in contact with” the second layer. For example, a cathode may be described as “disposed over” an anode, even though there are various organic layers in between.
As used herein, “solution processable” means capable of being dissolved, dispersed, or transported in and/or deposited from a liquid medium, either in solution or suspension form.
As used herein, and as would be generally understood by one skilled in the art, a first “Highest Occupied Molecular Orbital” (HOMO) or “Lowest Unoccupied Molecular Orbital” (LUMO) energy level is “greater than” or “higher than” a second HOMO or LUMO energy level if the first energy level is closer to the vacuum energy level. Since ionization potentials (IP) are measured as a negative energy relative to a vacuum level, a higher HOMO energy level corresponds to an IP having a smaller absolute value (an IP that is less negative). Similarly, a higher LUMO energy level corresponds to an electron affinity (EA) having a smaller absolute value (an EA that is less negative). On a conventional energy level diagram, with the vacuum level at the top, the LUMO energy level of a material is higher than the HOMO energy level of the same material. A “higher” HOMO or LUMO energy level appears closer to the top of such a diagram than a “lower” HOMO or LUMO energy level.
As used herein, and as would be generally understood by one skilled in the art, a first work function is “greater than” or “higher than” a second work function if the first work function has a higher absolute value. Because work functions are generally measured as negative numbers relative to vacuum level, this means that a “higher” work function is more negative. On a conventional energy level diagram, with the vacuum level at the top, a “higher” work function is illustrated as further away from the vacuum level in the downward direction. Thus, the definitions of HOMO and LUMO energy levels follow a different convention than work functions.
Layers, materials, regions, and devices may be described herein in reference to the color of light they emit. In general, as used herein, an emissive region that is described as producing a specific color of light may include one or more emissive layers disposed over each other in a stack.
As used herein, a “NIR”, “red”, “green”, “blue”, “yellow” layer, material, region, or device refers to a layer, a material, a region, or a device that emits light in the wavelength range of about 700-1500 nm, 580-700 nm, 500-600 nm, 400-500 nm, 540-600 nm, respectively, or a layer, a material, a region, or a device that has a highest peak in its emission spectrum in the respective wavelength region. In some arrangements, separate regions, layers, materials, or devices may provide separate “deep blue” and “light blue” emissions. As used herein, the “deep blue” emission component refers to an emission having a peak emission wavelength that is at least about 4 nm less than the peak emission wavelength of the “light blue” emission component. Typically, a “light blue” emission component has a peak emission wavelength in the range of about 465-500 nm, and a “deep blue” emission component has a peak emission wavelength in the range of about 400-470 nm, though these ranges may vary for some configurations.
In some arrangements, a color altering layer that converts, modifies, or shifts the color of the light emitted by another layer to an emission having a different wavelength is provided. Such a color altering layer can be formulated to shift wavelength of the light emitted by the other layer by a defined amount, as measured by the difference in the wavelength of the emitted light and the wavelength of the resulting light. In general, there are two classes of color altering layers: color filters that modify a spectrum by removing light of unwanted wavelengths, and color changing layers that convert photons of higher energy to lower energy. For example, a “red” color filter can be present in order to filter an input light to remove light having a wavelength outside the range of about 580-700 nm. A component “of a color” refers to a component that, when activated or used, produces or otherwise emits light having a particular color as previously described. For example, a “first emissive region of a first color” and a “second emissive region of a second color different than the first color” describes two emissive regions that, when activated within a device, emit two different colors as previously described.
As used herein, emissive materials, layers, and regions may be distinguished from one another and from other structures based upon light initially generated by the material, layer or region, as opposed to light eventually emitted by the same or a different structure. The initial light generation typically is the result of an energy level change resulting in emission of a photon. For example, an organic emissive material may initially generate blue light, which may be converted by a color filter, quantum dot or other structure to red or green light, such that a complete emissive stack or sub-pixel emits the red or green light. In this case the initial emissive material, region, or layer may be referred to as a “blue” component, even though the sub-pixel is a “red” or “green” component.
In some cases, it may be preferable to describe the color of a component such as an emissive region, sub-pixel, color altering layer, or the like, in terms of 1931 CIE coordinates. For example, a yellow emissive material may have multiple peak emission wavelengths, one in or near an edge of the “green” region, and one within or near an edge of the “red” region as previously described. Accordingly, as used herein, each color term also corresponds to a shape in the 1931 CIE coordinate color space. The shape in 1931 CIE color space is constructed by following the locus between two color points and any additional interior points. For example, interior shape parameters for red, green, blue, and yellow may be defined as shown below:
The terms “halo,” “halogen,” and “halide” are used interchangeably and refer to fluorine, chlorine, bromine, and iodine.
The term “acyl” refers to a substituted carbonyl group (—C(O)—Rs).
The term “ester” refers to a substituted oxycarbonyl (—O—C(O)—Rs or —C(O)—O—Rs) group.
The term “ether” refers to an —ORs group.
The terms “sulfanyl” or “thio-ether” are used interchangeably and refer to a —SRs group.
The term “selenyl” refers to a —SeRs group.
The term “sulfinyl” refers to a —S(O)—Rs group.
The term “sulfonyl” refers to a —SO2—Rs group.
The term “phosphino” refers to a group containing at least one phosphorus atom bonded to the relevant structure. Common examples of phosphino groups include, but are not limited to, groups such as a —P(Rs)2 group or a —PO(Rs)2 group, wherein each Rs can be same or different.
The term “silyl” refers to a group containing at least one silicon atom bonded to the relevant structure. Common examples of silyl groups include, but are not limited to, groups such as a —Si(Rs)3 group, wherein each Rs can be same or different.
The term “germyl” refers to a group containing at least one germanium atom bonded to the relevant structure. Common examples of germyl groups include, but are not limited to, groups such as a —Ge(Rs)3 group, wherein each Rs can be same or different.
The term “boryl” refers to a group containing at least one boron atom bonded to the relevant structure. Common examples of boryl groups include, but are not limited to, groups such as a —B(Rs)2 group or its Lewis adduct —B(Rs)3 group, wherein Rs can be same or different.
In each of the above, Rs can be hydrogen or a substituent selected from the group consisting of the General Substituents as defined in this application. Preferred Rs is selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, and combination thereof. More preferably Rs is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combination thereof.
The term “alkyl” refers to and includes both straight and branched chain alkyl groups having an alkyl carbon atom bonded to the relevant structure. Preferred alkyl groups are those containing from one to fifteen carbon atoms, preferably one to nine carbon atoms, and includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1,3-dimethylpropyl, 1,1-dimethylpropyl, 2-ethylpropyl, 1,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3,3-dimethylpentyl, 3-ethylpentyl, 2,2,3-trimethylbutyl, and the like. Additionally, the alkyl group can be further substituted.
The term “cycloalkyl” refers to and includes monocyclic, polycyclic, and spiro alkyl groups having a ring alkyl carbon atom bonded to the relevant structure. Preferred cycloalkyl groups are those containing 3 to 12 ring carbon atoms and includes cyclopropyl, cyclopentyl, cyclohexyl, bicyclo[3.1.1]heptyl, spiro[4.5]decyl, spiro[5.5]undecyl, adamantyl, and the like. Additionally, the cycloalkyl group can be further substituted.
The terms “heteroalkyl” or “heterocycloalkyl” refer to an alkyl or a cycloalkyl group, respectively, having at least one carbon atom replaced by a heteroatom. Optionally the at least one heteroatom is selected from O, S, N, P, B, Si, Ge and Se, preferably, O, S or N. Additionally, the heteroalkyl or heterocycloalkyl group can be further substituted.
The term “alkenyl” refers to and includes both straight and branched chain alkene groups. Alkenyl groups are essentially alkyl groups that include at least one carbon-carbon double bond in the alkyl chain with one carbon atom from the carbon-carbon double bond that is bonded to the relevant structure. Cycloalkenyl groups are essentially cycloalkyl groups that include at least one carbon-carbon double bond in the cycloalkyl ring. The term “heteroalkenyl” as used herein refers to an alkenyl group having at least one carbon atom replaced by a heteroatom. Optionally the at least one heteroatom is selected from O, S, N, P, B, Si, Ge, and Se, preferably, O, S, or N. Preferred alkenyl, cycloalkenyl, or heteroalkenyl groups are those containing two to fifteen carbon atoms. Additionally, the alkenyl, cycloalkenyl, or heteroalkenyl group can be further substituted.
The term “alkynyl” refers to and includes both straight and branched chain alkyne groups. Alkynyl groups are essentially alkyl groups that include at least one carbon-carbon triple bond in the alkyl chain with one carbon atom from the carbon-carbon triple bond that is bonded to the relevant structure. Preferred alkynyl groups are those containing two to fifteen carbon atoms. Additionally, the alkynyl group can be further substituted.
The terms “aralkyl” or “arylalkyl” are used interchangeably and refer to an aryl-substituted alkyl group having an alkyl carbon atom bonded to the relevant structure. Additionally, the aralkyl group can be further substituted.
The term “heterocyclic group” refers to and includes aromatic and non-aromatic cyclic groups containing at least one heteroatom. Optionally the at least one heteroatom is selected from O, S, Se, N, P, B, Si, Ge, and Se, preferably, O, S, N, or B. Hetero-aromatic cyclic groups may be used interchangeably with heteroaryl. Preferred hetero-non-aromatic cyclic groups are those containing 3 to 10 ring atoms, preferably those containing 3 to 7 ring atoms, which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperidino, pyrrolidino, and the like, and cyclic ethers/thio-ethers, such as tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, and the like. Additionally, the heterocyclic group can be further substituted or fused.
The term “aryl” refers to and includes both single-ring and polycyclic aromatic hydrocarbyl groups. The polycyclic rings may have two or more rings in which two carbons are common to two adjoining rings (the rings are “fused”). Preferred aryl groups are those containing six to thirty carbon atoms, preferably six to twenty-four carbon atoms, six to eighteen carbon atoms, and more preferably six to twelve carbon atoms. Especially preferred is an aryl group having six carbons, ten carbons, twelve carbons, fourteen carbons, or eighteen carbons. Suitable aryl groups include phenyl, biphenyl, triphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, pyrene, chrysene, perylene, and azulene, preferably phenyl, biphenyl, triphenyl, triphenylene, and naphthalene. Additionally, the aryl group can be further substituted or fused, such as, without limitation, fluorene.
The term “heteroaryl” refers to and includes both single-ring aromatic groups and polycyclic aromatic ring systems that include at least one heteroatom. The heteroatoms include, but are not limited to O, S, Se, N, P, B, Si, Ge, and Se. In many instances, O, S, N, or B are the preferred heteroatoms. Hetero-single ring aromatic systems are preferably single rings with 5 or 6 ring atoms, and the ring can have from one to six heteroatoms. The hetero-polycyclic ring systems can have two or more aromatic rings in which two atoms are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is a heteroaryl. The hetero-polycyclic aromatic ring systems can have from one to six heteroatoms per ring of the polycyclic aromatic ring system. Preferred heteroaryl groups are those containing three to thirty carbon atoms, preferably three to twenty-four carbon atoms, three to eighteen carbon atoms, and more preferably three to twelve carbon atoms. Suitable heteroaryl groups include dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, selenophenodipyridine, azaborine, borazine, 5λ2,9λ2-diaza-13b-boranaphtho[2,3,4-de]anthracene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, and 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene; preferably dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazole, pyridine, triazine, benzimidazole, 5λ2,9λ2-diaza-13b-boranaphtho[2,3,4-de]anthracene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, and 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene. Additionally, the heteroaryl group can be further substituted or fused.
Of the aryl and heteroaryl groups listed above, the groups of triphenylene, naphthalene, anthracene, dibenzothiophene, dibenzofuran, dibenzoselenophene, carbazole, indolocarbazole, imidazole, pyridine, pyrazine, pyrimidine, triazine, benzimidazole, 5λ2,9λ2-diaza-13b-boranaphtho[2,3,4-de]anthracene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene, and the respective aza-analogs of each thereof are of particular interest.
In many instances, the General Substituents are selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, selenyl, sulfinyl, sulfonyl, phosphino, and combinations thereof.
In some instances, the Preferred General Substituents are selected from the group consisting of deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, sulfanyl, and combinations thereof.
In some instances, the More Preferred General Substituents are selected from the group consisting of deuterium, fluorine, alkyl, cycloalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, aryl, heteroaryl, nitrile, sulfanyl, and combinations thereof.
In some instances, the Even More Preferred General Substituents are selected from the group consisting of deuterium, fluorine, alkyl, cycloalkyl, silyl, aryl, heteroaryl, nitrile, and combinations thereof.
In yet other instances, the Most Preferred General Substituents are selected from the group consisting of deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
The terms “substituted” and “substitution” refer to a substituent other than H that is bonded to the relevant position, e.g., a carbon or nitrogen. For example, when R1 represents mono-substitution, then one R1 must be other than H (i.e., a substitution). Similarly, when R1 represents di-substitution, then two of R1 must be other than H. Similarly, when R1 represents zero or no substitution, R1, for example, can be a hydrogen for all available valencies of ring atoms, as in carbon atoms for benzene and the nitrogen atom in pyrrole, or simply represents nothing for ring atoms with fully filled valencies, e.g., the nitrogen atom in pyridine. The maximum number of substitutions possible in a ring structure will depend on the total number of available valencies in the ring atoms.
As used herein, “combinations thereof” indicates that one or more members of the applicable list are combined to form a known or chemically stable arrangement that one of ordinary skill in the art can envision from the applicable list. For example, an alkyl and deuterium can be combined to form a partial or fully deuterated alkyl group; a halogen and alkyl can be combined to form a halogenated alkyl substituent; and a halogen, alkyl, and aryl can be combined to form a halogenated arylalkyl. In one instance, the term substitution includes a combination of two to four of the listed groups. In another instance, the term substitution includes a combination of two to three groups. In yet another instance, the term substitution includes a combination of two groups. Preferred combinations of substituent groups are those that contain up to fifty atoms that are not hydrogen or deuterium, or those which include up to forty atoms that are not hydrogen or deuterium, or those that include up to thirty atoms that are not hydrogen or deuterium. In many instances, a preferred combination of substituent groups will include up to twenty atoms that are not hydrogen or deuterium.
The “aza” designation in the fragments described herein, i.e. aza-dibenzofuran, aza-dibenzothiophene, etc. means that one or more of the C—H groups in the respective aromatic ring can be replaced by a nitrogen atom, for example, and without any limitation, azatriphenylene encompasses both dibenzo[f,h]quinoxaline and dibenzo[f,h]quinoline. One of ordinary skill in the art can readily envision other nitrogen analogs of the aza-derivatives described above, and all such analogs are intended to be encompassed by the terms as set forth herein.
As used herein, “deuterium” refers to an isotope of hydrogen. Deuterated compounds can be readily prepared using methods known in the art. For example, U.S. Pat. No. 8,557,400, Patent Pub. No. WO 2006/095951, and U.S. Pat. Application Pub. No. US 2011/0037057, which are hereby incorporated by reference in their entireties, describe the making of deuterium-substituted organometallic complexes. Further reference is made to Ming Yan, et al., Tetrahedron 2015, 71, 1425-30 and Atzrodt et al., Angew. Chem. Int. Ed. (Reviews) 2007, 46, 7744-65, which are incorporated by reference in their entireties, describe the deuteration of the methylene hydrogens in benzyl amines and efficient pathways to replace aromatic ring hydrogens with deuterium, respectively.
As used herein, any specifically listed substituent, such as, without limitation, methyl, phenyl, pyridyl, etc. includes undeuterated, partially deuterated, and fully deuterated versions thereof. Similarly, classes of substituents such as, without limitation, alkyl, aryl, cycloalkyl, heteroaryl, etc. also include undeuterated, partially deuterated, and fully deuterated versions thereof. Unless otherwise specified, atoms in chemical structures without valences fully filled by H or D should be considered to include undeuterated, partially deuterated, and fully deuterated versions thereof. For example, the chemical structure of
implies to include C6H6, C6D6, CH3D3, and any other partially deuterated variants thereof. Some common basic partially or fully deuterated groups include, without limitation, CD3, CD2C(CH3)3, C(CD3)3, and C6D5.
It is to be understood that when a molecular fragment is described as being a substituent or otherwise attached to another moiety, its name may be written as if it were a fragment (e.g. phenyl, phenylene, naphthyl, dibenzofuryl) or as if it were the whole molecule (e.g. benzene, naphthalene, dibenzofuran). As used herein, these different ways of designating a substituent or attached fragment are considered to be equivalent.
In some instances, a pair of substituents in the molecule can be joined or fused into a ring. The preferred ring is a five to nine-membered carbocyclic or heterocyclic ring, includes both instances where the portion of the ring formed by the pair of substituents is saturated and where the portion of the ring formed by the pair of substituents is unsaturated. In yet other instances, a pair of adjacent substituents can be joined or fused into a ring. As used herein, “adjacent” means that the two substituents involved can be on the same ring next to each other, or on two neighboring rings having the two closest available substitutable positions, such as 2, 2′ positions in a biphenyl, or 1, 8 position in a naphthalene.
In one aspect, the present disclosure provides a compound having a Formula Ir(LA)x(LB)y(Lc)z, wherein:
In some embodiments, at least one of moiety A or moiety B is a polycyclic fused ring system comprising at least four rings fused together. In some such embodiments, Formula II may be fused to the polycyclic fused ring system comprising at least four rings fused together. In some such embodiments, at least one RA′, RB′, RC′, or RD′ is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC′ or RD′ is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC′ or RD′ is deuterium. In some such embodiments, at last one RE is CD3.
In some embodiments, at least one of moiety A or moiety B is a polycyclic fused ring system comprising at least three rings fused together, and at least one of RA′, RB′, RC′, RD′, and RE independently comprises an electron withdrawing group, a silyl group, or a germyl group. In some such embodiments, Formula II may be fused to the polycyclic fused ring system comprising at least three rings fused together.
In some embodiments, at least one of moiety A or moiety B is carbazole, aza-carbazole, fluorene, or aza-fluorene.
In some embodiments, at least one of the following conditions is true:
In some embodiments, the compound is not:
In some embodiments, the compound has Formula Ir(LA)x(LB)y with a structure of Formula I:
With x is 1 and y is 2, or x is 2 and y is 1; and the remaining variables are the same as previously defined.
In some embodiments, Formula Ir(LA)x(LB)y has a structure of Formula I. In some embodiments, Formula Ir(LA)x(LB)y consists essentially of a structure of Formula I.
In some embodiments of Formula I, at least one RA′, RB′, RC′, or RD′ is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC′ or RD′ is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC′ or RD′ is deuterium. In some such embodiments, at last one RE is CD3.
In some embodiments, at least one RA′, RB′, RC′, RD′, or RE is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RA′ is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RB′ is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RC′ is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RD′ is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE is a substituent selected from the group consisting of the General Substituents defined herein.
In some embodiments of Formula I, at least one RA′, RB′, RC′, RD′, or RE is partially or fully deuterated. In some embodiments, at least one RA′ is partially or fully deuterated. In some embodiments, at least one RB′ is partially or fully deuterated. In some embodiments, at least one RC′ is partially or fully deuterated. In some embodiments, at least one RD′ is partially or fully deuterated. In some embodiments, at least one RE is partially or fully deuterated.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D is independently a monocyclic ring or a polycyclic fused ring system, wherein the monocyclic ring or each ring of the polycyclic fused ring system is independently a 5-membered or 6-membered carbocyclic or heterocyclic ring.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D is independently a monocyclic ring or a polycyclic fused ring system, wherein the monocyclic ring or each ring of the polycyclic fused ring system is independently a 5-membered or 6-membered aryl or heteroaryl ring.
In some embodiments, each RA′, RB′, RC′, RD′, and RE is independently hydrogen or a substituent selected from the group consisting of the Preferred General Substituents defined herein. In some embodiments, each RA′, RB′, RC′, RD′, and RE is independently hydrogen or a substituent selected from the group consisting of the More Preferred General Substituents defined herein. In some embodiments, each RA′, RB′, RC′, RD′, and RE is independently hydrogen or a substituent selected from the group consisting of the Most Preferred General Substituents defined herein.
In some embodiments, x is 1 and y is 2. In some embodiments, x is 2 and y is 1.
In some embodiments, W1 is N and each of W2, W5, and W6 is C.
In some embodiments, W1 is carbene C, W5 is N, and W2 and W6 are C.
In some embodiments, W3 is N and each of W4, W7, and W8 is C.
In some embodiments, W3 is carbene C, W7 is N, and W4 and W8 are C.
In some embodiments, a structure of Formula II is fused to moiety A.
In some embodiments, moiety A is a polycyclic fused ring system comprising at least four rings fused together. In some embodiments, moiety A is a polycyclic fused ring system comprising at least five rings fused together. In some embodiments, the structure of Formula II is fused to the distal ring of the polycyclic fused ring system of moiety A. In some embodiments, the structure of Formula II is fused to a ring other than the distal ring of the polycyclic fused ring system of moiety A. As used herein, the “distal” ring refers to the ring of the polycyclic fused ring system that is farthest away from the Ir atom.
In some embodiments, moiety A is not a polycyclic fused ring system comprising at least four rings fused together (i.e., moiety B is a monocyclic ring or a polycyclic fused ring system comprising up to three rings fused together).
In some embodiments, the structure of Formula II is fused to moiety B.
In some embodiments, moiety B is a polycyclic fused ring system comprising at least four rings fused together. In some embodiments, moiety B is a polycyclic fused ring system comprising at least five rings fused together. In some embodiments, the structure of Formula II is fused to the distal ring of the polycyclic fused ring system of moiety B. In some embodiments, the structure of Formula II is fused to a ring other than the distal ring of the polycyclic fused ring system of moiety B. As used herein, the “distal” ring refers to the ring of the polycyclic fused ring system that is farthest away from the Ir atom.
In some embodiments, moiety B is not a polycyclic fused ring system comprising at least four rings fused together (i.e., moiety B is a monocyclic ring or a polycyclic fused ring system comprising up to three rings fused together).
In some embodiments, a structure of Formula II is fused to moiety C.
In some embodiments, moiety C is a monocyclic ring. In some embodiments, moiety C is pyridine. In some embodiments when moiety C is pyridine and Formula II is fused to the pyridine, then at least one RC or one RD is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC or one RD is a deuterium. In some embodiments when moiety C is pyridine and Formula II is fused to the pyridine and moiety D is a monocyclic benzene ring, then at least one RE is an EWG group, a silyl group, a germyl group, or CD3. In some such embodiments, at least one RE is CD3. In some embodiments, moiety C is a polycyclic fused ring system. In some such embodiments, Formula II is fused to the polycyclic fused ring system.
In some embodiments, a structure of Formula II is fused to moiety D.
In some embodiments, moiety D is a monocyclic ring. In some embodiments, moiety D is benzene. In some embodiments when moiety D is benzene and Formula II is fused to the benzene and moiety C is a monocyclic pyridine ring, then at least one RC or one RD is a deuterium, an EWG group, a silyl group, or a germyl group. In some such embodiments, at least one RC or one RD is a deuterium. In some embodiments when moiety D is benzene and Formula II is fused to the benzene, then at least one RE is an EWG group, a silyl group, a germyl group, or CD3. In some such embodiments, at least one RE is CD3.
In some embodiments, moiety D is a polycyclic fused ring system. In some such embodiments, Formula II is fused to the polycyclic fused ring system.
In some embodiments, at least one structure of Formula II is fused to moiety A or moiety B. In some embodiments, at least one structure of Formula II is fused to moiety A. In some embodiments, at least one structure of Formula II is fused to moiety B.
In some embodiments, at least one structure of Formula II is fused to moiety C or moiety D. In some embodiments, at least one structure of Formula II is fused to moiety C. In some embodiments, at least one structure of Formula II is fused to moiety D.
In some embodiments, at least one structure of Formula II is fused to moiety A or moiety B, and at least one structure of Formula II is fused to moiety C or moiety D.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D is a moiety independently selected from the group consisting of the Cyclic Moiety List or two structures of the Cyclic Moiety List fused together; wherein the Cyclic Moiety List is defined as benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, triazole, naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene.
In some embodiments, moiety A is a monocyclic ring. In some embodiments, moiety A is selected from the group consisting of benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, inidazole derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole. In some embodiments, moiety A is pyridine or imidazole.
In some embodiments, moiety A is a polycyclic fused ring system. In some embodiments, moiety A is selected from the group consisting of naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, moiety A is quinoline, isoquinoline, or benzimidazole.
In some embodiments, moiety A comprises at least four rings fused together. In some embodiments, moiety A comprises at least five rings fused together.
In some embodiments, the ring containing W1 is part of a moiety A1 selected from the group consisting of carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, the ring containing W1 is pyridine or imidazole. In some embodiments, the ring containing W1 is pyridine. In some embodiments, the ring containing W1 is imidazole.
In some embodiments, moiety A1 is annulated by a moiety A2 selected from the group consisting of the Cyclic Moiety List defined herein. In some embodiments, moiety A2 is benzene, naphthalene, benzofuran, or benzothiophene. In some embodiments, moiety A2 is benzene. In some embodiments, moiety A2 is naphthalene.
In some embodiments, moiety A1 is aza-dibenzofuran and A2 is benzene or naphthalene.
In some embodiments, moiety B is a monocyclic ring. In some embodiments, moiety B is selected from the group consisting of benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole. In some embodiments, moiety B is pyridine or imidazole.
In some embodiments, moiety B is a polycyclic fused ring system. In some embodiments, moiety B is selected from the group consisting of naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, moiety B is quinoline, isoquinoline, or benzimidazole.
In some embodiments, moiety B comprises at least four rings fused together. In some embodiments, moiety B comprises at least five rings fused together.
In some embodiments, the ring containing W2 is part of a moiety B1 selected from the group consisting of carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, the ring containing W2 is benzene.
In some embodiments, moiety B1 is annulated by a moiety B2 selected from the group consisting of the Cyclic Moiety List defined herein. In some embodiments, moiety B2 is benzene, naphthalene, benzofuran, or benzothiophene. In some embodiments moiety B is benzene. In some embodiments, moiety B is naphthalene.
In some embodiments, moiety B1 is dibenzofuran and B2 is benzene or naphthalene.
In some embodiments, moiety C is a monocyclic ring. In some embodiments, moiety C is selected from the group consisting of benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole. In some embodiments, moiety C is pyridine or imidazole.
In some embodiments, moiety C is a polycyclic fused ring system. In some embodiments, moiety C is selected from the group consisting of naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, moiety C is naphthalene or benzimidazole.
In some embodiments, moiety D is a monocyclic ring. In some embodiments, moiety D is selected from the group consisting of benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole. In some embodiments, moiety D is benzene.
In some embodiments, moiety D is a polycyclic fused ring system. In some embodiments, moiety D is selected from the group consisting of naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, moiety D is naphthalene.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be a polycyclic fused ring structure. In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be a polycyclic fused ring structure comprising at least three fused rings. In some embodiments, the polycyclic fused ring structure has two 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused to the ring coordinated to the Ir atom and the second 6-membered ring is fused to the 5-membered ring. In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be selected from the group consisting of dibenzofuran, dibenzothiophene, dibenzoselenophene, and aza-variants thereof. In some such embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be further substituted at the ortho- or meta-position of the O, S, or Se atom by a substituent selected from the group consisting of deuterium, fluorine, nitrile, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some such embodiments, the aza-variants contain exactly one N atom at the 6-position (ortho to the O, S, or Se) with a substituent at the 7-position (meta to the O, S, or Se).
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be a polycyclic fused ring structure comprising at least four fused rings. In some embodiments, the polycyclic fused ring structure comprises three 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused to the ring coordinated to the Ir atom, the second 6-membered ring is fused to the 5-membered ring, and the third 6-membered ring is fused to the second 6-membered ring. In some such embodiments, the third 6-membered ring is further substituted by a substituent selected from the group consisting of deuterium, fluorine, nitrile, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be a polycyclic fused ring structure comprising at least five fused rings. In some embodiments, the polycyclic fused ring structure comprises four 6-membered rings and one 5-membered ring or three 6-membered rings and two 5-membered rings. In some embodiments comprising two 5-membered rings, the 5-membered rings are fused together. In some embodiments comprising two 5-membered rings, the 5-membered rings are separated by at least one 6-membered ring. In some embodiments with one 5-membered ring, the 5-membered ring is fused to the ring coordinated to the Ir atom, the second 6-membered ring is fused to the 5-membered ring, the third 6-membered ring is fused to the second 6-membered ring, and the fourth 6-membered ring is fused to the third 6-membered ring.
In some embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently be an aza version of the polycyclic fused rings described above. In some such embodiments, each of moiety A, moiety B, moiety C, and moiety D can independently contain exactly one aza N atom. In some such embodiments, each of moiety A, moiety B, moiety C, and moiety D contains exactly two aza N atoms, which can be in one ring, or in two different rings. In some such embodiments, the ring having aza N atom is separated by at least two other rings from the Ir atom. In some such embodiments, the ring having aza N atom is separated by at least three other rings from the Ir atom. In some such embodiments, each of the ortho positions of the aza N atom is substituted.
In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
In some embodiments, the compound comprises an electron-withdrawing group. In some embodiments, the electron-withdrawing group has a Hammett constant larger than 0. In some embodiments, the electron-withdrawing group has a Hammett constant equal or larger than 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, or 1.1.
In some embodiments, Formula Ir(LA)x(LB)y comprises an electron-withdrawing group selected from the group consisting of the following EWG1 LIST: F, CF3, CN, COCH3, CHO, COCF3, COOMe, COOCF3, NO2, SF3, SiF3, PF4, SF5, OCF3, SCF3, SeCF3, SOCF3, SeOCF3, SO2F, SO2CF3, SeO2CF3, OSeO2CF3, OCN, SCN, SeCN, NC, +N(Rk2)3, (Rk2)2CCN, (Rk2)2CCF3, CNC(CF3)2, BRk3Rk2, substituted or unsubstituted dibenzoborole, 1-substituted carbazole, 1,9-substituted carbazole, substituted or unsubstituted carbazole, substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyridoxine, substituted or unsubstituted triazine, substituted or unsubstituted oxazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted imidazole, substituted or unsubstituted benzimidazole, ketone, carboxylic acid, ester, nitrile, isonitrile, sulfinyl, sulfonyl, partially and fully fluorinated alkyl, partially and fully fluorinated aryl, partially and fully fluorinated heteroaryl, cyano-containing alkyl, cyano-containing aryl, cyano-containing heteroaryl, isocyanate,
In some embodiments, Formula Ir(LA)x(LB)y comprises an electron-withdrawing group selected from the group consisting of the structures of the following EWG2 List:
In some embodiments, Formula Ir(LA)x(LB)y comprises an electron-withdrawing group selected from the group consisting of the structures of the following EWG3 LIST:
In some embodiments, Formula Ir(LA)x(LB)y comprises an electron-withdrawing group selected from the group consisting of the structures of the following EWG4 LIST:
In some embodiments, Formula Ir(LA)x(LB)y comprises an electron-withdrawing group that is a π-electron deficient electron-withdrawing group. In some embodiments, the π-electron deficient electron-withdrawing group is selected from the group consisting of the structures of the following Pi-EWG LIST: CN, COCH3, CHO, COCF3, COOMe, COOCF3, NO2, SF3, SiF3, PF4, SF5, OCF3, SCF3, SeCF3, SOCF3, SeOCF3, SO2F, SO2CF3, SeO2CF3, OSeO2CF3, OCN, SCN, SeCN, NC, +N(Rk2)3, BRk2Rk3, substituted or unsubstituted dibenzoborole, 1-substituted carbazole, 1,9-substituted carbazole, substituted or unsubstituted carbazole, substituted or unsubstituted pyridine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyridazine, substituted or unsubstituted triazine, substituted or unsubstituted oxazole, substituted or unsubstituted benzoxazole, substituted or unsubstituted thiazole, substituted or unsubstituted benzothiazole, substituted or unsubstituted imidazole, substituted or unsubstituted benzimidazole, ketone, carboxylic acid, ester, nitrile, isonitrile, sulfinyl, sulfonyl, partially and fully fluorinated aryl, partially and fully fluorinated heteroaryl, cyano-containing aryl, cyano-containing heteroaryl, isocyanate,
wherein the variables are the same as previously defined.
In some embodiments, ligand LA comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, ligand LA comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, ligand LA comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, ligand LA comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, ligand LA comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, ligand LB comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, ligand LB comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, ligand LB comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, ligand LB comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, ligand LB comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RA′ is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RA′ is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RA′ is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RA′ is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RA′ is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RB′ is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RB′ is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RB′ is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RB′ is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RB′ is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RC′ is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RC′ is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RC′ is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RD′ is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RD′ is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RD′ is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RD is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RD is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RA′ that is not part of Formula II is not hydrogen.
In some embodiments, at least one RA′ that is not part of Formula II comprises at least one C atom. In some embodiments, at least one RA′ that is not part of Formula II comprises at least three C atoms. In some embodiments, at least one RA′ that is not part of Formula II comprises at least four C atoms.
In some embodiments, at least one RA′ that is not part of Formula II comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, at least one RB′ that is not part of Formula II is not hydrogen.
In some embodiments, at least one RB′ that is not part of Formula II comprises at least one C atom. In some embodiments, at least one RB′ that is not part of Formula II comprises at least three C atoms. In some embodiments, at least one RB′ that is not part of Formula II comprises at least four C atoms.
In some embodiments, at least one RB′ that is not part of Formula II comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, at least one RC′ that is not part of Formula II is not hydrogen.
In some embodiments, at least one RC′ that is not part of Formula II comprises at least one C atom. In some embodiments, at least one RC′ that is not part of Formula II comprises at least three C atoms. In some embodiments, at least one RC′ that is not part of Formula II comprises at least four C atoms.
In some embodiments, at least one RC′ that is not part of Formula II comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, at least one RD′ that is not part of Formula II is not hydrogen.
In some embodiments, at least one RD′ that is not part of Formula II comprises at least one C atom. In some embodiments, at least one RD′ that is not part of Formula II comprises at least three C atoms. In some embodiments, at least one RD′ that is not part of Formula II comprises at least four C atoms.
In some embodiments, at least one RD′ that is not part of Formula II comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, at least one RE is not hydrogen.
In some embodiments, at least one RE comprises at least one C atom. In some embodiments, at least two RE each independently comprise at least one C atom. In some embodiments, at least three RE each independently comprise at least one C atom. In some embodiments, at least four RE each independently comprise at least one C atom.
In some embodiments, at least one RE comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, wherein at least two RE each independently comprise a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, any RE on the same carbon are the same. In some such embodiments, each RE on the same carbon is methyl. In some such embodiments, each RE on the same carbon is ethyl.
In some embodiments, two RE on adjacent carbons are joined or fused to form a ring. In some embodiments, two RE on the same carbon are joined to form a spiro ring.
In some embodiments, the structure of Formula II is selected from the structures of the following LIST 1A:
wherein ring G or ring E is a 5-membered to 10 membered carbocyclic or heterocyclic ring; RG represents mono to the maximum allowable substitution, or no substitution;
In some embodiments where a structure is from the LIST 1A, at least one RG, RE, RE1, RE2, RE3, RE4, RE5, and RE6 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RG is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE1 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE2 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE3 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE4 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE5 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE6 is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments where a structure is from the LIST 1A, at least one RG, RE, RE1, RE2, RE3, RE4, RE5, and RE6 comprises at least two carbon atoms.
In some of embodiments where a structure is from the LIST 1A, RE1 and RE2 may be joined to form a spiro structure when they are attached to the same carbon atom.
In some of embodiments where a structure is from the LIST 1A, RE3 and RE4 may be joined to form a spiro structure when they are attached to the same carbon atom.
In some of embodiments where a structure is from the LIST 1A, RE5 and RE6 may be joined to form a spiro structure when they are attached to the same carbon atom.
In some of the above embodiments, the spiro ring may be a 5-membered to 10 membered carbocyclic or heterocyclic ring.
In some of embodiments where a structure is from the LIST 1A, at least one of RE1, RE2, RE3, RE4, RE5, and RE6 is an electron withdrawing group.
In some embodiments, the structure of Formula II is selected from the structures of the following LIST 1:
In some embodiments, the ligand LA is selected from the group consisting of the structure of the following LIST 2:
In some embodiments where ligand LA is selected from LIST 2, at least one pair of RAA or RBB are joined to form a structure of Formula II when LB ligand does not comprise a structure of Formula II.
In some embodiments where ligand LA is selected from LIST 2, at least one RAA or RBB is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RAA is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RBB is a substituent selected from the group consisting of the General Substituents defined herein.
In some embodiments where ligand LA is selected from LIST 2, at least one RAA, RBB, RN, Re, and Rf is partially or fully deuterated. In some embodiments, at least one RAA is partially or fully deuterated. In some embodiments, at least one RBB is partially or fully deuterated. In some embodiments, at least one RN is partially or fully deuterated. In some embodiments, at least one Re or Rf is partially or fully deuterated.
In some embodiments where ligand LA is selected from LIST 2, at least one RAA is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 2, at least one RBB is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 2, at least one RN is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 2, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, the ligand LA is selected from the group consisting of the structures of the following LIST 2a:
wherein:
In some embodiments where ligand LA is selected from LIST 2a, at least one pair of RA′, RB1, RB2, or RB3 are joined to form a structure of Formula II when LB ligand does not comprise a structure of Formula II.
In some embodiments, the ligand LA is selected from the group consisting of the structures of the following LIST 3:
In some embodiments where ligand LA is selected from LIST 3, at least one pair of RAA, RBB, or RC are joined to for a structure of Formula II when LB ligand does not comprise a structure of Formula II.
In some embodiments where ligand LA is selected from LIST 3, at least one RAA, RBB, or RC is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RAA is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RBB is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RC is a substituent selected from the group consisting of the General Substituents defined herein.
In some embodiments where ligand LA is selected from LIST 3, at least one of Re, Rf, RAA, RBB, RC, or RN is partially or fully deuterated. In some embodiments, at least one RAA is partially or fully deuterated. In some embodiments, at least one RBB is partially or fully deuterated. In some embodiments, at least one RC is partially or fully deuterated. In some embodiments, at least one RN is partially or fully deuterated. In some embodiments, at least one Re or Rf is partially or fully deuterated.
In some embodiments where ligand LA is selected from LIST 3, at least one RAA is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RAA is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 3, at least one RBB is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RBB is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 3, at least one RC is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RC is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 3, at least one RN is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA is selected from LIST 3, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one Re or Rf is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, the ligand LA is selected from LA′w(GA)(RH)(RI)(RJ)(RK), wherein w is an integer from 1 to 72, and each of RH, RI, RJ, and RK is independently selected from the group consisting of V1 to V148; GA is selected from G1 to G57; and each of LA′1(G1)(V1)(V1)(V1)(V1) to LA′72(G57)(V148)(V148)(V148)(V148) is defined in the following LIST 3a:
In some embodiments, the ligand LA is selected from LA*w′(RH)(RI)(RJ)(RK) wherein w′ is an integer from 1 to 28, and each of RH, RI, RJ, and RK is independently selected from the group consisting of V1 to V148; and each of LA*1(V1)(V1)(V1)(V1) to LA*28(V148)(V148)(V148)(V148) is defined below (LIST 3b):
In some embodiments, ligand LA is selected from LAi, wherein i is an integer from 1 to 420, and each of LA1 to LA420 is defined in the following LIST 4:
In some embodiments, LB is selected from the group consisting of the structures of the following LIST 5:
In some embodiments where LB is selected from LIST 5 defined herein, at least two adjacent Ra1, Rb1, Rc1, Rd1, Ra, Rb, Rc, and Rd are joined or fused to form a structure of Formula II when LA does not comprise a structure of Formula II. In some embodiments where LB is selected from LIST 5 defined herein, two adjacent Ra1, Rb1, Rc1, Rd1, Ra, Rb, Rc, or Rd are joined or fused to form a structure of Formula II even if LA also comprises a structure of Formula II. In some embodiments, LB is selected from the group consisting of the structures of the following LIST 6:
wherein:
In some embodiments where LB is selected from LIST 6 defined herein, at least two adjacent Ra′, Rb′, Rc′, Rd′, or Re′ are joined or fused to form a structure of Formula II when LA does not comprise a structure of Formula II. In some embodiments where LB is selected from LIST 6 defined herein, two adjacent Ra′, Rb′, Rc′, Rd′, or Re′ are joined or fused to form a structure of Formula II even if LA also comprises a structure of Formula II.
In some embodiments, LB comprises a structure of
wherein the variables are the same as previously defined. In some embodiments, each of Y1 to Y4 is independently carbon. In some embodiments, at least one of Y1 to Y4 is N. In some embodiments, exactly one of Y1 to Y4 is N. In some embodiments, Y1 is N. In some embodiments, Y2 is N. In some embodiments, Y3 is N. In some embodiments, Y4 is N. In some embodiments, at least one of Ra is a tertiary alkyl, silyl or germyl. In some embodiments, at least one of Ra is a tertiary alkyl. In some embodiments, Y3 is C and the Ra attached thereto is a tertiary alkyl, silyl or germyl. In some embodiments, Y1 to Y3 is C, Y4 is N, and the Ra attached to Y3 is a tertiary alkyl, silyl or germyl. In some embodiments, Y1 to Y3 is C, Y4 is N, and the Ra attached to Y2 is a tertiary alkyl, silyl or germyl. In some embodiments, at least one of Rb is a tertiary alkyl, silyl, or germyl. In some embodiments, the tertiary alkyl is tert-butyl. In some embodiments, at least one pair of Ra, one pair of Rb, or one pair of Ra and Rb are joined or fused into a ring.
In some embodiments, LA can be selected from LAi, wherein i is an integer from 1 to 420; and LB can be selected from LBk, wherein k is an integer from 1 to 530, wherein:
In some embodiments, LB is selected from LB′g wherein g is an integer from 1 to 57, and each LB′g is defined in the following LIST 6a:
In some embodiments, LA can be selected from LA′w(GA)(RH)(RI)(RJ)(RK), wherein w is an integer from 1 to 72; and LB can be selected from LBk, wherein k is an integer from 1 to 530, and LB can be selected from LBk, wherein:
In some embodiments, LA can be selected from LA*w′(RH)(RI)(RJ)(RK), wherein w′ is an integer from 1 to 28; and LB can be selected from LB′g, wherein g is an integer from 1 to 57, wherein:
In some embodiments, LA can be selected from LA′w(GA)(RH)(RI)(RJ)(RK), wherein w is an integer from 1 to 72; and LB can be selected from LB′g, wherein is an integer from 1 to 57, wherein:
In some embodiments, the compound is selected from the group consisting of the structures of the following LIST 8:
In another aspect, an Ir complex comprising a ligand LA″ with a structure comprising Formula III;
comprising a structure of Formula II,
is fused to ring H or ring G is provided. In Formula III:
In some embodiments of Formula III, if ring F is pyridine, then each of the following is true:
In some embodiments, the ligand LA″ has a structure of Formula III. In some embodiments, the ligand LA″ has a structure consisting essentially of Formula III.
Although described in separate aspects, it should be understood that teachings applicable to LA can also be applicable to LA″. Similarly, LA and LA″ can be interchangeable in some embodiments (e.g., LA″ can be used with the LB of compounds of Formula I, while LA can be used with LB or LC of compounds comprising Formula III).
In some embodiments of Formula III, at least one RE, RF, RG, or RH is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RE is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RF is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RG is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RH is a substituent selected from the group consisting of the General Substituents defined herein
In some embodiments of Formula III, at least one R, R′, RE, RF, RG, and RH is partially or fully deuterated. In some embodiments, at least one RE is partially or fully deuterated. In some embodiments, at least one RF is partially or fully deuterated. In some embodiments, at least one RG is partially or fully deuterated. In some embodiments, at least one RH is partially or fully deuterated. In some embodiments, at least one R or R′ is partially or fully deuterated.
In some embodiments of Formula III, moiety F is a monocyclic ring or a polycyclic fused ring system, wherein the monocyclic ring or each ring of the polycyclic fused ring system is independently a 5-membered or 6-membered carbocyclic or heterocyclic ring.
In some embodiments of Formula III, moiety F is a monocyclic ring or a polycyclic fused ring system, wherein the monocyclic ring or each ring of the polycyclic fused ring system is independently a 5-membered or 6-membered aryl or heteroaryl ring.
In some embodiments of Formula III, each R, R′, RE, RF, RG, and RH is independently hydrogen or a substituent selected from the group consisting of deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, germyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, sulfanyl, and combinations thereof.
In some embodiments of Formula III, X10 is N and X9 is C.
In some embodiments of Formula III, X10 is carbene carbon and X9 is N.
In some embodiments of Formula III, each of X1 to X8 is carbon. In some embodiments of Formula III, at least one of X1 to X8 is N. In some embodiments of Formula III, exactly one of X1 to X8 is N.
In some embodiments of Formula III, each of X1 to X4 is C. In some embodiments of Formula III, at least one of X1 to X4 is N. In some embodiments of Formula III, exactly one of X1 to X4 is N.
In some embodiments of Formula III, each of X5 to X8 is C. In some embodiments of Formula III, at least one of X5 to X8 is N. In some embodiments of Formula III, exactly one of X5 to X8 is N.
In some embodiments of Formula III, YA is selected from the group consisting of O, S, and Se. In some embodiments, YA is O. In some embodiments, YA is selected from the group consisting of BR, NR, and PR. In some embodiments, YA is BR. In some embodiments, YA is NR. In some embodiments, YA is PR. In some embodiments, YA is selected from the group consisting of P(O)R, C═O, C═S, C═Se, C═NR′, C═CRR′, S═O, and SO2. In some embodiments, YA is selected from the group consisting of BRR′, CRR′, SiRR′, and GeRR′. In some embodiments, YA is CR.
In some embodiments, the ring comprising YA is fused to ring G at X3 and X4. In some embodiments, the ring comprising YA is fused to ring G at X2 and X3. In some embodiments, the ring comprising YA is fused to ring G at X1 and X2.
In some embodiments, the structure of Formula II is fused to ring G. In some embodiments, the structure of Formula II is fused to ring G at X1 and X2. In some embodiments, the structure of Formula II is fused to ring G at X3 and X4.
In some embodiments, moiety F is selected from the group consisting of the Cyclic Moiety List defined herein.
In some embodiments, moiety F is a monocyclic ring. In some embodiments, moiety F is selected from the group consisting of benzene, pyridine, pyrimidine, pyridazine, pyrazine, triazine, imidazole, imidazole derived carbene, pyrazole, pyrrole, oxazole, furan, thiophene, thiazole, and triazole. In some embodiments, moiety F is pyridine or imidazole.
In some embodiments, moiety F is a polycyclic fused ring system. In some embodiments, moiety F is selected from the group consisting of naphthalene, quinoline, isoquinoline, quinazoline, benzofuran, aza-benzofuran, phenanthro[3,2-b]benzofuran, benzoxazole, aza-benzoxazole, benzothiophene, aza-benzothiophene, benzothiazole, aza-benzothiazole, benzoselenophene, aza-benzoselenophene, indene, aza-indene, indole, aza-indole, benzimidazole, aza-benzimidazole, benzimidazole derived carbene, aza-benzimidazole derived carbene, benzobenzimidazole, aza-benzobenzimidazole, carbazole, aza-carbazole, dibenzofuran, aza-dibenzofuran, dibenzothiophene, aza-dibenzothiophene, quinoxaline, phthalazine, phenanthrene, aza-phenanathrene, anthracene, aza-anthracene, phenanthridine, fluorene, and aza-fluorene. In some embodiments, moiety F is quinoline, isoquinoline, or benzimidazole.
In some embodiments, moiety F can be a polycyclic fused ring structure. In some embodiments, moiety F can be a polycyclic fused ring structure comprising at least three fused rings. In some embodiments, the polycyclic fused ring structure has two 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused to the ring coordinated to the Ir atom and the second 6-membered ring is fused to the 5-membered ring. In some embodiments, moiety F can be selected from the group consisting of dibenzofuran, dibenzothiophene, dibenzoselenophene, and aza-variants thereof. In some such embodiments, moiety F can be further substituted at the ortho- or meta-position of the O, S, or Se atom by a substituent selected from the group consisting of deuterium, fluorine, nitrile, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some such embodiments, the aza-variants contain exactly one N atom at the 6-position (ortho to the O, S, or Se) with a substituent at the 7-position (meta to the O, S, or Se).
In some embodiments, moiety F can be a polycyclic fused ring structure comprising at least four fused rings. In some embodiments, the polycyclic fused ring structure comprises three 6-membered rings and one 5-membered ring. In some such embodiments, the 5-membered ring is fused to the ring coordinated to the Ir atom, the second 6-membered ring is fused to the 5-membered ring, and the third 6-membered ring is fused to the second 6-membered ring. In some such embodiments, the third 6-membered ring is further substituted by a substituent selected from the group consisting of deuterium, fluorine, nitrile, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, moiety F can be a polycyclic fused ring structure comprising at least five fused rings. In some embodiments, the polycyclic fused ring structure comprises four 6-membered rings and one 5-membered ring or three 6-membered rings and two 5-membered rings. In some embodiments comprising two 5-membered rings, the 5-membered rings are fused together. In some embodiments comprising two 5-membered rings, the 5-membered rings are separated by at least one 6-membered ring. In some embodiments with one 5-membered ring, the 5-membered ring is fused to the ring coordinated to the Ir atom, the second 6-membered ring is fused to the 5-membered ring, the third 6-membered ring is fused to the second 6-membered ring, and the fourth 6-membered ring is fused to the third 6-membered ring.
In some embodiments, moiety F can be an aza version of the polycyclic fused rings described above. In some such embodiments, moiety F can contain exactly one aza N atom. In some such embodiments, moiety F can contain exactly two aza N atoms, which can be in one ring, or in two different rings. In some such embodiments, the ring having aza N atom is separated by at least two other rings from the Ir atom. In some such embodiments, the ring having aza N atom is separated by at least three other rings from the Ir atom. In some such embodiments, each of the ortho positions of the aza N atom is substituted.
In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
In some embodiments, the structure of Formula II is fused to ring H at X5 and X6. In some embodiments, the structure of Formula II is fused to ring H at X6 and X7. In some embodiments, the structure of Formula II is fused to ring H at X7 and X8.
In some embodiments, Formula III comprises an electron-withdrawing group selected from the group consisting of the EWG1 LIST defined herein. In some embodiments, Formula III comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, Formula III comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, Formula III comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, Formula III comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, the compound comprising ligand LA″ comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, the compound comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, the compound comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, the compound comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, the compound comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RE is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one R or R′ is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one R or R′ is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one R or R′ is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one R or R′ is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one R or R′ is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, at least one RF is not hydrogen. In some embodiments, at least one RF comprises at least one C atom. In some embodiments, at least one RF comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, at least one RG is not hydrogen. In some embodiments, at least one RG comprises at least one C atom. In some embodiments, at least one RG comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, two RG are joined or fused to form a ring.
In some embodiments, at least one RH is not hydrogen. In some embodiments, at least one RH comprises at least one C atom. In some embodiments, at least one RH comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, two RH are joined or fused to form a ring in addition to the structure of Formula II.
In some embodiments, at least one RE is not hydrogen. In some embodiments, at least one RE comprises at least one C atom. In some embodiments, each of at least two RE independently comprises at least one C atom. In some embodiments, each of at least three RE independently comprises at least one C atom. In some embodiments, each of at least four RE independently comprises at least one C atom.
In some embodiments, at least one RE comprises a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof. In some embodiments, at least two RE independently comprise a substituent selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof.
In some embodiments, any RE on the same carbon are the same. In some embodiments, any RE on the same carbon are methyl. In some embodiments, any RE on the same carbon are ethyl.
In some embodiments, two RE on adjacent carbons are joined or fused to forma ring.
In some embodiments, two RE on the same carbon are not H. In some embodiments, two RE on the same carbon are joined or fused to form a ring.
In some embodiments of Formula I or Formula III, the structure of Formula II may be selected from the group consisting of the structures of LIST 1 defined herein.
In some embodiments of Formula I or Formula III, the structure of Formula II may be selected from the group consisting of the structures of LIST 1A defined herein.
In some embodiments, the ligand LA″ is selected from the group consisting of the structures of the following LIST 9:
In some embodiments where ligand LA″ is selected from LIST 9, at least one RF, RG, or RH is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RF is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RG is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RH is a substituent selected from the group consisting of the General Substituents defined herein.
In some embodiments, where ligand LA″ is selected from LIST 9, at least one of RF, RG, RH, or RN is partially or fully deuterated. In some embodiments, at least one RF is partially or fully deuterated. In some embodiments, at least one RG is partially or fully deuterated. In some embodiments, at least one RH is partially or fully deuterated. In some embodiments, at least one RN is partially or fully deuterated.
In some embodiments where ligand LA″ is selected from LIST 9, at least one RF is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 9, at least one RG is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 9, at least one RH is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 9, at least one RN is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, the ligand LA″ is selected from the group consisting of the structures of the following LIST 10:
In some embodiments where ligand LA″ is selected from LIST 10, at least one RF, RG, or RH is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RF is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RG is a substituent selected from the group consisting of the General Substituents defined herein. In some embodiments, at least one RH is a substituent selected from the group consisting of the General Substituents defined herein.
In some embodiments where ligand LA″ is selected from LIST 10, at least one of RF, RG, RH, or RN is partially or fully deuterated. In some embodiments, at least one RF is partially or fully deuterated. In some embodiments, at least one RG is partially or fully deuterated. In some embodiments, at least one RH is partially or fully deuterated. In some embodiments, at least one RN is partially or fully deuterated.
In some embodiments where ligand LA″ is selected from LIST 10, at least one RF is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RF is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 10, at least one RG is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RG is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 10, at least one RH is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RH is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments where ligand LA″ is selected from LIST 10, at least one RN is or comprises an electron-withdrawing group from the EWG1 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG2 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG3 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the EWG4 LIST as defined herein. In some embodiments, at least one RN is or comprises an electron-withdrawing group from the Pi-EWG LIST as defined herein.
In some embodiments, the ligand LA″ is selected from LAw, wherein w is an integer from 1 to 463, and each of LA″1 to LA″463 is defined in the following LIST 11:
In some embodiments, the compound has a formula of Ir(LA″)p(LB)q(LC)r wherein LB and LC are each a bidentate ligand; and wherein p is 1, 2, or 3; q is 0, 1, or 2; r is 0, 1, or 2; and p+q+r is the oxidation state of the metal M.
In some embodiments, the compound has a formula selected from the group consisting of Ir(LA″)3, Ir(LA″)(LB)2, Ir(LA″)2(LB), Ir(LA″)2(LC), and Ir(LA″)(LB)(LC); and wherein LA″, LB, and LC are different from each other.
In some embodiments, LB is a substituted or unsubstituted phenylpyridine, and LC is a substituted or unsubstituted acetylacetonate.
In some embodiments, the compound has a formula of Pt(LA″)(LB); and wherein LA″ and LB can be same or different. In some embodiments, LA″ and LB are connected to form a tetradentate ligand.
In some embodiments, LB and LC are each independently selected from the group consisting of:
and the structures of LIST 5 defined herein,
In some embodiments, LB and LC are each independently selected from the group consisting of
and the structures of LIST 6 defined herein;
In some embodiments, the compound has formula Ir(LA″)3, formula Ir(LA″)(LBk)2, formula Ir(LA″)2(LBk), formula Ir(LA″)2(LCj-1), or formula Ir(LA″)2(LCj-II),
In some embodiments, the compound is selected from the group consisting of only those compounds whose LBk corresponds to one of the following: LB1, LB30, LB31, LB109, LB110, LB112, LB113, LB114, LB125, LB127, LB138, LB140, LB149, LB150, LB170, LB171, LB172, LB174, LB208, LB241, LB312, LB315, LB356, LB367, LB371, LB382, LB439, LB440, LB455, LB456, LB457, LB458, LB461, LB462, LB463, LB469, and LB476.
In some embodiments, the compound is selected from the group consisting of only those compounds whose LBk corresponds to one of the following: LB1, LB30, LB31, LB125, LB138, LB171, LB172, LB356, LB357, LB367, LB371, LB382, LB455, and LB456.
In some embodiments, the compound is selected from the group consisting of only those compounds having LCj-I or LCj-II ligand whose corresponding R201 and R202 are defined to be one of the following structures: RD1, RD3, RD4, RDS, RD9, RD10, RD17, RD18, RD20, RD22, RD37, RD40, RD41, RD42, RD43, RD48, RD49, RD50, RD54, RD55, RD58, RD59, RD78, RD79, RD81, RD87, RD88, RD89, RD93, RD116, RD117, RD118, RD119, RD120, RD133, RD134, RD135, RD136, RD143, RD144, RD145, RD146, RD147, RD149, RD151, RD154, RD155, RD161, RD175, RD190, RD193, RD200, RD201, RD206, RD210, RD214, RD215, RD216, RD218, RD219, RD220, RD227, RD237, RD241, RD242, RD245, and RD246.
In some embodiments, the compound is selected from the group consisting of only those compounds having LCj-I or LCj-II ligand whose corresponding R201 and R202 are defined to be one of selected from the following structures: RD1, RD3, RD4, RD5, RD9, RD10, RD17, RD22, RD43, RD50, RD78, RD116, RD118, RD133, RD134, RD135, RD136, RD143, RD144, RD145, RD146, RD149, RD151, RD154, RD155, RD190, RD193, RD200, RD201, RD206, RD210, RD214, RD215, RD216, RD218, RD219, RD220, RD227, RD237, RD241, RD242, RD245, and RD246.
In some embodiments, the compound is selected from the group consisting of only those compounds having one of the structures of the following LIST 14 for the LCj-I ligand:
In some embodiments, the compound has a formula selected from the group consisting of Ir(LA″)3, Ir(LA″)2(LB), Ir(LA″)(LB)2, Ir(LA″)2(LC), and Ir(LA″)(LB)(LC). In some embodiments, LA″ is selected from the group consisting of the structures of LIST 9, LIST 10, and LIST 11, LB is selected from the group consisting of the structures of LIST 5, LIST 6, and LIST 7 (LBk), and LC is selected from the group consisting of the structures of LCj-I and LCj-II defined herein.
In some embodiments, LA″ is selected from the group consisting of the structures of LIST 9 and LB is selected from the group consisting of the structures of LBk. In some embodiments, LA″ is selected from the group consisting of the structures of LIST 10 and LB is selected from the group consisting of the structures of LBk. In some embodiments, LA″ is selected from the group consisting of the structures of LIST 11 and LB is selected from the group consisting of the structures of LBk, wherein k is an integer from 1 to 530. In some embodiments, LA″ is selected from LIST 11 defined herein, and LC is selected from the group consisting of the structures of LCj-I and LCj-II wherein j is an integer from 1 to 1416.
In some embodiments, the compound can have the formula Ir(LA″w)3 consisting of the compounds of Ir(LA″1)3 to Ir(LA″463)3, the formula Ir(LA″w)(LB)2, the formula Ir(LA″w)2(LB), the formula Ir(LA″)(LBk)2, the formula Ir(LA″)2(LBk), the formula Ir(LA″w)(LBk)2 consisting of the compounds of Ir(LA″1)(LB1)2 to Ir(LA″463)(LB530)2, the formula Ir(LA″w)2(LBk) consisting of the compounds of Ir(LA″1)2(LB1) to Ir(LA″463)2(LB530), the formula Ir(LA″w)2(LCj-I) consisting of the compounds of Ir(LA″1)2(LC1-I) to Ir(LA″463)2(LC1416-1), the formula Ir(LA″w)2(LCj-II) consisting of the compounds of Ir(LA″1)2(LC1-II) to Ir(LA″463)2(LC1416-II), the formula Ir(LA″w)(LBk)(LCj- I) consisting of the compounds of Ir(LA″1)(LB1)(LC1-I) to Ir(LA″463)(LB530)(LC1416-I), or the formula Ir(LA″w)(LBk)(LCj-II) consisting of the compounds of Ir(LA″1)(LB1)(LC1-II) to Ir(LA″463)(LB530)(LC1416-II), wherein LA″w, LBk, and LCj-I and LCj-II are all defined herein.
In some embodiments, the compound is selected from the group consisting of the structures of the following LIST 15:
In some embodiments, the compound having the formula of Ir(LA)x(LB)y(Lc)z or Ir(LA″)p(LB)q(LC)r described herein can be at least 30% deuterated, at least 40% deuterated, at least 50% deuterated, at least 60% deuterated, at least 70% deuterated, at least 80% deuterated, at least 90% deuterated, at least 95% deuterated, at least 99% deuterated, or 100% deuterated. As used herein, percent deuteration has its ordinary meaning and includes the percent of all possible hydrogen atoms in the compound (e.g., positions that are hydrogen or deuterium) that are occupied by deuterium atoms. In some embodiments, carbon atoms comprised the ring coordinated to the metal M are fully or partially deuterated. In some embodiments, carbon atoms comprised by a polycyclic ring system coordinated to the metal M are fully or partially deuterated. In some embodiments, a substituent attached to a monocyclic or fused polycyclic ring system coordinated to the metal M is fully or partially deuterated.
In some embodiments, the compound of formula I has an emission at room temperature with a full width at half maximum (FWHM) of equal to or less than 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 nm. Narrower FWHM means better color purity for the OLED display application.
In some embodiments of heteroleptic compound having the formula of Ir(LA)x(LB)y(Lc)z or Ir(LA″)p(LB)(LC)r as defined above, the ligand LA or LA″ has a first substituent RI, where the first substituent RI has a first atom a-I that is the farthest away from the metal M among all atoms in the ligand LA. Additionally, the ligand LB, if present, has a second substituent RII, where the second substituent RII has a first atom a-II that is the farthest away from the metal M among all atoms in the ligand LB. Furthermore, the ligand LC, if present, has a third substituent RIII, where the third substituent RIII has a first atom a-III that is the farthest away from the metal M among all atoms in the ligand LC.
In such heteroleptic compounds, vectors VD1, VD2, and VD3 can be defined as follows. VD1 represents the direction from the metal M to the first atom a-I and the vector VD1 has a value D1 that represents the straight line distance between the metal M and the first atom a-I in the first substituent RI. VD2 represents the direction from the metal M to the first atom a-II and the vector VD2 has a value D2 that represents the straight line distance between the metal M and the first atom a-II in the second substituent RII. VD3 represents the direction from the metal M to the first atom a-III and the vector VD3 has a value D3 that represents the straight line distance between the metal M and the first atom a-III in the third substituent RIII.
In such heteroleptic compounds, a sphere having a radius r is defined whose center is the metal M and the radius r is the smallest radius that will allow the sphere to enclose all atoms in the compound that are not part of the substituents RI, RII and RIII; and where at least one of D1, D2, and D3 is greater than the radius r by at least 1.5 Å. In some embodiments, at least one of D1, D2, and D3 is greater than the radius r by at least 2.9, 3.0, 4.3, 4.4, 5.2, 5.9, 7.3, 8.8, 10.3, 13.1, 17.6, or 19.1 Å. In some embodiments, at least two of D1, D2, and D3 is greater than the radius r by at least 1.5, 2.9, 3.0, 4.3, 4.4, 5.2, 5.9, 7.3, 8.8, 10.3, 13.1, 17.6, or 19.1 Å.
In some embodiments of such heteroleptic compound, the compound has a transition dipole moment axis and angles are defined between the transition dipole moment axis and the vectors VD1, VD2, and VD3, where at least one of the angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 is less than 40°. In some embodiments, at least one of the angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 is less than 30°, 20°, 15°, or 10°. In some embodiments, at least two of the angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 are less than 20°. In some embodiments, at least two of the angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 are less than 15° or 10°.
In some embodiments, all three angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 are less than 20°. In some embodiments, all three angles between the transition dipole moment axis and the vectors VD1, VD2, and VD3 are less than 150 or 10°.
In some embodiments of such heteroleptic compounds, the compound has a vertical dipole ratio (VDR) of 0.33 or less. In some embodiments of such heteroleptic compounds, the compound has a VDR of 0.30, 0.25, 0.20, or 0.15 or less.
One of ordinary skill in the art would readily understand the meaning of the terms transition dipole moment axis of a compound and vertical dipole ratio of a compound. Nevertheless, the meaning of these terms can be found in U.S. Pat. No. 10,672,997 whose disclosure is incorporated herein by reference in its entirety. In U.S. Pat. No. 10,672,997, horizontal dipole ratio (HDR) of a compound, rather than VDR, is discussed. However, one skilled in the art readily understands that VDR=1−HDR.
In some embodiments, the compound can be an emissive dopant. In some embodiments, the compound can produce emissions via phosphorescence, fluorescence, thermally activated delayed fluorescence, triplet-triplet annihilation, or combinations of these processes. In some embodiments, the emissive dopant can be a racemic mixture, or can be enriched in one enantiomer. In some embodiments, the present compounds can have different stereoisomers, such as fac and mer. The current compound relates both to individual isomers and to mixtures of various isomers in any mixing ratio. In some embodiments, the compound can be homoleptic (each ligand is the same). In some embodiments, the compound can be heteroleptic (at least one ligand is different from others). When there are more than one ligand coordinated to a metal, the ligands can all be the same in some embodiments. In some other embodiments, at least one ligand is different from the other ligands. In some embodiments, every ligand can be different from every other ligand. This is also true in embodiments where a ligand being coordinated to a metal can be linked with other ligands being coordinated to that metal to form a tridentate, tetradentate, pentadentate, or hexadentate ligands. Thus, where the coordinating ligands are being linked together, all of the ligands can be the same in some embodiments, and at least one of the ligands being linked can be different from the other ligand(s) in some other embodiments.
In yet another aspect of the present disclosure, a formulation that comprises the novel compound disclosed herein is described. The formulation can include one or more components selected from the group consisting of a solvent, an emitter, a host, a hole injection material, hole transport material, electron blocking material, hole blocking material, and an electron transport material, disclosed herein.
The present disclosure encompasses any chemical structure comprising the novel compound of the present disclosure, or a monovalent or polyvalent variant thereof. In other words, the inventive compound, or a monovalent or polyvalent variant thereof, can be a part of a larger chemical structure. Such chemical structure can be selected from the group consisting of a monomer, a polymer, a macromolecule, and a supramolecule (also known as supermolecule). As used herein, a “monovalent variant of a compound” refers to a moiety that is identical to the compound except that one hydrogen has been removed and replaced with a bond to the rest of the chemical structure. As used herein, a “polyvalent variant of a compound” refers to a moiety that is identical to the compound except that more than one hydrogen has been removed and replaced with a bond or bonds to the rest of the chemical structure. In the instance of a supramolecule, the inventive compound can also be incorporated into the supramolecule complex without covalent bonds. As used in this context, the description that a structure A comprises a moiety B means that the structure A includes the structure of moiety B not including the H or D atoms that can be attached to the moiety B. This is because at least one H or D on a given moiety structure has to be replaced to become a substituent so that the moiety B can be part of the structure A, and one or more of the H or D on a given moiety B structure can be further substituted once it becomes a part of structure A.
In another aspect, the present disclosure also provides an OLED device comprising a first organic layer that contains a compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the OLED comprises: an anode; a cathode; and an organic layer disposed between the anode and the cathode, where the organic layer comprises a compound having a Formula Ir(LA)x(LB)y(Lc)z or Ir(LA″)p(LB)q(LC)r defined herein.
In some embodiments, the organic layer is selected from the group consisting of HIL, HTL, EBL, EML, HBL, ETL, and EIL. In some embodiments, the organic layer may be an emissive layer and the compound as described herein may be an emissive dopant or a non-emissive dopant.
In some embodiments, the organic layer may further comprise a host, wherein host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene, azaborinine, oxaborinine, dihydroacridine, xanthene, dihydrobenzoazasiline, dibenzooxasiline, phenoxazine, phenoxathiine, phenothiazine, dihydrophenazine, fluorene, naphthalene, anthracene, phenanthrene, phenanthroline, benzoquinoline, quinoline, isoquinoline, quinazoline, pyrimidine, pyrazine, pyridine, triazine, boryl, silyl, aza-triphenylene, aza-carbazole, aza-indolocarbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, and aza-(5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene).
In some embodiments, the host can be selected from the group consisting of the structures of the following HOST Group 1:
In some embodiments at least one of J1 to J3 is N. In some embodiments at least two of J1 to J3 are N. In some embodiments, all three of J1 to J3 are N. In some embodiments, each YCC and YDD is independently O, S, or SiRR′, or more preferably O or S. In some embodiments, at least one unsubstituted aromatic carbon atom is replaced with N to form an aza-ring.
In some embodiments, the host is selected from the group consisting of EG1-MG1-EG1 to EG53-MG27-EG53 with a formula of EGa-MGb-EGc, or EG1-EG1 to EG53-EG53 with a formula of EGa-EGc when MGb is absent, wherein a is an integer from 1 to 53, b is an integer from 1 to 27, c is an integer from 1 to 53. The structure of EG1 to EG53 is shown below:
The structures of MG1 to MG27 are shown below:
In the MGb structures shown above, the two bonding positions in the asymmetric structures MG1, MG11, MG12, MG13, MG14, MG17, MG24, and MG25 are labeled with numbers for identification purposes.
In some embodiments, the host can be any of the aza-substituted variants thereof, fully or partially deuterated variants thereof, and combinations thereof. In some embodiments, the host has formula EGa-MGb-Egc and is selected from the group consisting of h1 to h112 defined in the following HOST Group 2 list, where each of MGb, EGa, and EGc are defined as follows:
In the table above, the EGa and EGc structures that are bonded to one of the asymmetric structures MG10, MG11, MG12, MG13, MG14, MG17, MG24, and MG25, are noted with a numeric prefix identifying their bonding position in the MGb structure.
In some embodiments, the organic layer may further comprise a host, wherein the host comprises a metal complex.
In some embodiments, the emissive layer can comprise two hosts, a first host and a second host. In some embodiments, the first host is a hole transporting host, and the second host is an electron transporting host. In some embodiments, the first host is a hole transporting host, and the second host is a bipolar host. In some embodiments, the first host is an electron transporting host, and the second host is a bipolar host. In some embodiments, the first host and the second host can form an exciplex. In some embodiments, the emissive layer can comprise a third host. In some embodiments, the third host is selected from the group consisting of an insulating host (wide band gap host), a hole transporting host, and an electron transporting host. In some embodiments, the third host forms an exciplex with one of the first host and the second host, or with both the first host and the second host. In some embodiments, the emissive layer can comprise a fourth host. In some embodiments, the fourth host is selected from the group consisting of an insulating host (wide band gap host), a hole transporting host, and an electron transporting host. In some embodiments, the fourth host forms an exciplex with one of the first host, the second host, and the third host, with two of the first host, the second host, and the third host, or with each of the first host, the second host, and the third host. In some embodiments, the electron transporting host has a LUMO less than −2.4 eV, less than −2.5 eV, less than −2.6 eV, or less than −2.7 eV. In some embodiments, the hole transporting host has a HOMO higher than −5.6 eV, higher than −5.5 eV, higher than −5.4 eV, or higher than −5.35 eV. The HOMO and LUMO values can be determined using solution electrochemistry. Solution cyclic voltammetry and differential pulsed voltammetry can be performed using a CH Instruments model 6201B potentiostat using anhydrous dimethylformamide (DMF) solvent and tetrabutylammonium hexafluorophosphate as the supporting electrolyte. Glassy carbon, platinum wire, and silver wire were used as the working, counter and reference electrodes, respectively. Electrochemical potentials can be referenced to an internal ferrocene-ferroconium redox couple (Fc/Fc+) by measuring the peak potential differences from differential pulsed voltammetry. The corresponding highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies can be determined by referencing the cationic and anionic redox potentials to ferrocene (4.8 eV vs. vacuum) according to literature ((a) Fink, R.; Heischikel, Y.; Thelakkat, M.; Schmidt, H.-W. Chem. Mater. 1998, 10, 3620-3625. (b) Pommerehne, J.; Vestweber, H. Guss, W; Mahrt, R. F.; Bassler, H.; Porsch, M.; Daub, J. Adv. Mater 1995, 7, 551).
In some embodiments, the compound as described herein may be a sensitizer or a component of a sensitizer; wherein the device may further comprise an acceptor that receives the energy from the sensitizer. In some embodiments, the acceptor is an emitter in the device. In some embodiments, the acceptor may be a fluorescent material. In some embodiments, the compound described herein can be used as a phosphorescent sensitizer in an OLED where one or multiple layers in the OLED contain an acceptor in the form of one or more non-delayed fluorescent and/or delayed fluorescence material. In some embodiments, the compound described herein can be used as one component of an exciplex to be used as a sensitizer. As a phosphorescent sensitizer, the compound must be capable of energy transfer to the acceptor and the acceptor will emit the energy or further transfer energy to a final emitter. The acceptor concentrations can range from 0.001% to 99.9%. The acceptor could be in either the same layer as the phosphorescent sensitizer or in one or more different layers. In some embodiments, the acceptor is a thermally activated delayed fluorescence (TADF) material. In some embodiments, the acceptor is a non-delayed fluorescent material. In some embodiments, the emission can arise from any or all of the sensitizer, acceptor, and final emitter. In some embodiments, the acceptor has an emission at room temperature with a full width at half maximum (FWHM) of equal to or less than 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 nm. Narrower FWHM means better color purity for the OLED display application.
As used herein, phosphorescence generally refers to emission of a photon with a change in electron spin quantum number, i.e., the initial and final states of the emission have different electron spin quantum numbers, such as from T1 to S0 state. Most of the Ir and Pt complexes currently used in OLED are phosphorescent emitters. In some embodiments, if an exciplex formation involves a triplet emitter, such exciplex can also emit phosphorescent light. On the other hand, fluorescent emitters generally refer to emission of a photon without a change in electron spin quantum number, such as from Si to SO state, or from D1 to D0 state. Fluorescent emitters can be delayed fluorescent or non-delayed fluorescent emitters. Depending on the spin state, fluorescent emitter can be a singlet emitter or a doublet emitter, or other multiplet emitter. It is believed that the internal quantum efficiency (IQE) of fluorescent OLEDs can exceed the 25% spin statistics limit through delayed fluorescence. There are two types of delayed fluorescence, i.e. P-type and E-type delayed fluorescence. P-type delayed fluorescence is generated from triplet-triplet annihilation (TTA). On the other hand, E-type delayed fluorescence does not rely on the collision of two triplets, but rather on the thermal population between the triplet states and the singlet excited states. Thermal energy can activate the transition from the triplet state back to the singlet state. This type of delayed fluorescence is also known as TADF. E-type delayed fluorescence characteristics can be found in an exciplex system or in a single compound. Without being bound by theory, it is believed that TADF emissions require a compound or an exciplex having a small singlet-triplet energy gap (ΔES-T) less than or equal to 400, 350, 300, 250, 200, 150, 100, or 50 meV. There are two major types of TADF emitters, one is called donor-acceptor type TADF, the other one is called multiple resonance (MR) TADF. Often, single compound donor-acceptor TADF compounds are constructed by connecting an electron donor moiety such as amino- or carbazole-derivatives and an electron acceptor moiety such as N-containing six-membered aromatic rings or cyano-substituted aromatic rings. Donor-acceptor exciplexes can be formed between a hole transporting compound and an electron transporting compound. Examples of MR-TADF materials include highly conjugated fused ring systems. In some embodiments, MR-TADF materials comprises boron, carbon, and nitrogen atoms. Such materials may comprise other atoms, such as oxygen, as well. In some embodiments, the reverse intersystem crossing time from T1 to Si of the delayed fluorescent emission at 293K is less than or equal to 10 microseconds. In some embodiments, such time can be greater than 10 microseconds and less than 100 microseconds.
In some embodiments, the OLED may comprise an additional compound selected from the group consisting of a non-delayed fluorescence material, a delayed fluorescence material, a phosphorescent material, and combination thereof.
In some embodiments, the inventive compound described herein is a phosphorescent material.
In some embodiments, the phosphorescent material is an emitter which emits light within the OLED. In some embodiments, the phosphorescent material does not emit light within the OLED. In some embodiments, the phosphorescent material energy transfers its excited state to another material within the OLED. In some embodiments, the phosphorescent material participates in charge transport within the OLED. In some embodiments, the phosphorescent material is a sensitizer or a component of a sensitizer, and the OLED further comprises an acceptor. In some embodiments, the phosphorescent material forms an exciplex with another material within the OLED, for example a host material, an emitter material.
In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material is an emitter which emits light within the OLED. In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material does not emit light within the OLED. In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material energy transfers its excited state to another material within the OLED. In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material participates in charge transport within the OLED. In some embodiments, the non-delayed fluorescence material or the delayed fluorescence material is an acceptor, and the OLED further comprises a sensitizer.
In some embodiments of the OLED, the delayed fluorescence material comprises at least one donor group and at least one acceptor group. In some embodiments, the delayed fluorescence material is a metal complex. In some embodiments, the delayed fluorescence material is a non-metal complex. In some embodiments, the delayed fluorescence material is a Pt, Pd, Zn, Cu, Ag, or Au complex (some of them are also called metal-assisted (MA) TADF). In some embodiments, the metal-assisted delayed fluorescence material comprises a metal-carbene bond. In some embodiments, the non-delayed fluorescence material or delayed fluorescence material comprises at least one chemical group selected from the group consisting of aryl-amine, aryloxy, arylthio, triphenylene, carbazole, indolocarbazole, dibenzothiophene, dibenzofuran, dibenzoselenophene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene, 5λ2,9λ2-diaza-13b-boranaphtho[2,3,4-de]anthracene, 5-oxa-9λ2-aza-13b-boranaphtho[3,2,1-de]anthracene, azaborinine, oxaborinine, dihydroacridine, xanthene, dihydrobenzoazasiline, dibenzooxasiline, phenoxazine, phenoxathiine, phenothiazine, dihydrophenazine, fluorene, naphthalene, anthracene, phenanthrene, phenanthroline, benzoquinoline, quinoline, isoquinoline, quinazoline, pyrimidine, pyrazine, pyridine, triazine, boryl, amino, silyl, aza-variants thereof, and combinations thereof. In some embodiments, non-delayed the fluorescence material or delayed fluorescence material comprises a tri(aryl/heteroaryl)borane with one or more pairs of the substituents from the aryl/heteroaryl being joined to form a ring. In some embodiments, the fluorescence material comprises at least one chemical group selected from the group consisting of naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene.
In yet another aspect, the OLED of the present disclosure may also comprise an emissive region containing a compound or a formulation of the compound as disclosed in the above compounds section of the present disclosure. In some embodiments, the emissive region can comprise a compound or a formulation of the compound having a Formula Ir(LA)x(LB)y(Lc)z or Ir(LA″)p(LB)(LC)r defined herein. In some embodiments, the emissive region consists of one or more organic layers, wherein at least one of the one or more organic layers has a minimum thickness selected from the group consisting of 350, 400, 450, 500, 550, 600, 650 and 700 Å. In some embodiments, the at least one of the one or more organic layers are formed from an Emissive System that has a figure of merit (FOM) value equal to or larger than the number selected from the group consisting of 2.50, 2.55, 2.60, 2.65, 2.70, 2.75, 2.80, 2.85, 2.90, 2.95, 3.00, 5.00, 10.0, 15.0, and 20.0. The definition of FOM is available in U.S. patent Application Publication No. 2023/0292605, and its entire contents are incorporated herein by reference. In some embodiments, the at least one of the one or more organic layers comprises a compound or a formulation of the compound as disclosed in Sections A and D of the present disclosure.
In some embodiments, the OLED or the emissive region comprising the inventive compound disclosed herein can be incorporated into a full-color pixel arrangement of a device. The full-color pixel arrangement of such a device comprises at least one pixel, wherein the at least one pixel comprises a first subpixel and a second subpixel. The first subpixel includes a first OLED comprising a first emissive region. The second subpixel includes a second OLED comprising a second emissive region. In some embodiments, the first and/or second OLED, the first and/or second emissive region can be the same or different and each can independently have the various device characteristics and the various embodiments of the inventive compounds included therein, and various combinations and subcombinations of the various device characteristics and the various embodiments of the inventive compounds included therein, as disclosed herein.
In some embodiments, the first emissive region is configured to emit a light having a peak wavelength λmax1; the second emissive region is configured to emit a light having a peak wavelength λmax2. In some embodiments, the difference between the peak wavelengths λmax1 and λmax2 is at least 4 nm but within the same color. For example, a light blue and a deep blue light as described above. In some embodiments, a first emissive region is configured to emit a light having a peak wavelength λmax1 in one region of the visible spectrum of 400-500 nm, 500-600 nm, 600-700 nm; and a second emissive region is configured to emit light having a peak wavelength λmax2 in one of the remaining regions of the visible spectrum of 400-500 nm, 500-600 nm, 600-700 nm. In some embodiments, the first emissive region comprises a first number of emissive layers that are deposited one over the other if more than one; and the second emissive region comprises a second number of emissive layers that is deposited one over the other if more than one; and the first number is different from the second number. In some embodiments, both the first emissive region and the second emissive region comprise a phosphorescent material, which may be the same or different. In some embodiments, the first emissive region comprises a phosphorescent material, while the second emissive region comprises a fluorescent material. In some embodiments, both the first emissive region and the second emissive region comprise a fluorescent material, which may be the same or different.
In some embodiments, the at least one pixel of the OLED or emissive regions includes a total of N subpixels; wherein the N subpixels comprises the first subpixel and the second subpixel; wherein each of the N subpixels comprises an emissive region; wherein the total number of the emissive regions within the at least one pixel is equal to or less than N−1. In some embodiments, the second emissive region is exactly the same as the first emissive region; and each subpixel of the at least one pixel comprises the same one emissive region as the first emissive region. In some embodiments, the full-color pixel arrangements can have a plurality of pixels comprising a first pixel region and a second pixel region; wherein at least one display characteristic in the first pixel region is different from the corresponding display characteristic of the second pixel region, and wherein the at least one display characteristic is selected from the group consisting of resolution, cavity mode, color, outcoupling, and color filter.
In some embodiments, the OLED is a stacked OLED comprising one or more charge generation layers (CGLs). In some embodiments, the OLED comprises a first electrode, a first emissive region disposed over the first electrode, a first CGL disposed over the first emissive region, a second emissive region disposed over the first CGL, and a second electrode disposed over the second emissive region. In some embodiments, the first and/or the second emissive regions can have the various device characteristics as described above for the pixelated device. In some embodiments, the stacked OLED is configured to emit white color. In some embodiments, one or more of the emissive regions in a pixelated or in a stacked OLED comprises a sensitizer and an acceptor with the various sensitizing device characteristics and the various embodiments of the inventive compounds disclosed herein. For example, the first emissive region is comprised in a sensitizing device, while the second emissive region is not comprised in a sensitizing device; in some instances, both the first and the second emissive regions are comprised in sensitizing devices.
In some embodiments, the OLED can emit light having at least 1%, 5%, 10, 30%, 50%, 70%, 80%, 90%, 95%, 99%, or 100% from the plasmonic mode. In some embodiments, at least one of the anode, the cathode, or a new layer disposed over the organic emissive layer functions as an enhancement layer. The enhancement layer comprises a plasmonic material exhibiting surface plasmon resonance that non-radiatively couples to the emitter material and transfers excited state energy from the emitter material to non-radiative mode of surface plasmon polariton. In some embodiments, the enhancement layer is provided no more than a threshold distance away from the organic emissive layer, wherein the emitter material has a total non-radiative decay rate constant and a total radiative decay rate constant due to the presence of the enhancement layer. A threshold distance is where the total non-radiative decay rate constant is equal to the total radiative decay rate constant. Another threshold distance is the distance at which the total radiative decay rate constant divided by the sum of the total non-radiative decay rate constant and total radiative decay rate constant is equal to the photoluminescent yield of the emissive material without the enhancement layer present.
In some embodiments, the OLED further comprises an outcoupling layer. In some embodiments, the outcoupling layer is disposed over the enhancement layer on a side opposite the organic emissive layer The outcoupling layer scatters the energy from the surface plasmon polaritons. In some embodiments this energy is scattered as photons to free space. In other embodiments, the energy is scattered from the surface plasmon mode into other modes of the device such as but not limited to the organic waveguide mode, the substrate mode, or another waveguiding mode. In some embodiments, one or more intervening layer can be disposed between the enhancement layer and the outcoupling layer. The examples for intervening layer(s) can be dielectric materials, including organic, inorganic, perovskites, oxides, and may include stacks and/or mixtures of these materials.
The enhancement layer modifies the effective properties of the medium in which the emitter material resides resulting in any or all of the following: a decreased rate of emission, a modification of emission line-shape, a change in emission intensity with angle, a change in the stability of the emitter material, a change in the efficiency of the OLED, and a reduced efficiency roll-off of the OLED device. Placement of the enhancement layer on the cathode side, anode side, or on both sides, or the enhancement layer itself being as the CGL, results in OLED devices which take advantage of any of the above-mentioned effects. In addition to the specific functional layers mentioned herein and illustrated in the various OLED examples shown in the figures, the OLEDs according to the present disclosure may include any of the other functional layers often found in OLEDs.
In some embodiments, the enhancement layer can be comprised of plasmonic materials, optically active metamaterials, or hyperbolic metamaterials. In some embodiments, the plasmonic material includes at least one metal. In such embodiments the metal may include at least one of Ag, Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, or Ca, alloys or mixtures of these materials, and stacks of these materials. In some embodiments, the enhancement layer is provided as a planar layer. In other embodiments, the enhancement layer has wavelength-sized features that are arranged periodically, quasi-periodically, or randomly, or sub-wavelength-sized features that are arranged periodically, quasi-periodically, or randomly.
In some embodiments, the outcoupling layer has wavelength-sized or sub-wavelength sized features that are arranged periodically, quasi-periodically, or randomly. In some embodiments, the outcoupling layer may be composed of a plurality of nanoparticles. In some embodiments, the outcoupling layer is composed of a plurality of nanoparticles disposed over a material. In these embodiments the outcoupling layer may be tunable by at least one of: varying a size of the plurality of nanoparticles, varying a shape of the plurality of nanoparticles, changing a material of the plurality of nanoparticles, adjusting a thickness of the material, changing the refractive index of the material, adding an additional layer disposed on the plurality of nanoparticles, varying a thickness of the enhancement layer, or varying the material of the enhancement layer. The plurality of nanoparticles of the device may be formed from at least one of metal, dielectric material, semiconductor materials, an alloy of metal, a mixture of dielectric materials, a stack or layering of one or more materials, and/or a core of one type of material and that is coated with a shell of a different type of material. In some embodiments, the outcoupling layer is composed of at least metal nanoparticles wherein the metal is selected from the group consisting of Ag, Al, Au, Ir, Pt, Ni, Cu, W, Ta, Fe, Cr, Mg, Ga, Rh, Ti, Ru, Pd, In, Bi, and Ca, alloys or mixtures of these materials, and stacks of these materials. In some embodiments the outcoupling layer is formed by lithography.
In some embodiments of a plasmonic device, the emitter, and/or host compounds used in the emissive layer has a vertical dipole ratio (VDR) of 0.33 or more. In some such embodiments, the emitter, and/or host compounds have a VDR of 0.40, 0.50, 0.60, 0.70, or more.
In yet another aspect, the present disclosure also provides a consumer product comprising an organic light-emitting device (OLED) having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer may comprise a compound or a formulation of the compound as disclosed in the above compounds section of the present disclosure.
In some embodiments, the consumer product comprises an OLED having an anode; a cathode; and an organic layer disposed between the anode and the cathode, wherein the organic layer may comprise a compound having a Formula Ir(LA)x(LB)y(Lc)z or Ir(LA″)p(LB)q(LC)r defined herein.
Generally, an OLED comprises at least one organic layer disposed between and electrically connected to an anode and a cathode. When a current is applied, the anode injects holes and the cathode injects electrons into the organic layer(s). The injected holes and electrons each migrate toward the oppositely charged electrode. When an electron and hole localize on the same molecule, and an “exciton,” which is a localized electron-hole pair having an excited energy state, is formed. Light is emitted when the exciton relaxes via a photoemissive mechanism. In some cases, the exciton may be localized as an excimer or an exciplex. Non-radiative mechanisms, such as thermal relaxation, may also occur, but are generally considered undesirable.
More examples for each of these layers are available. For example, a flexible and transparent substrate-anode combination is disclosed in U.S. Pat. No. 5,844,363, which is incorporated by reference in its entirety. An example of a p-doped hole transport layer is m-MTDATA doped with F4-TCNQ at a molar ratio of 50:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. Examples of emissive and host materials are disclosed in U.S. Pat. No. 6,303,238 to Thompson et al., which is incorporated by reference in its entirety. An example of an n-doped electron transport layer is BPhen doped with Li at a molar ratio of 1:1, as disclosed in U.S. Patent Application Publication No. 2003/0230980, which is incorporated by reference in its entirety. U.S. Pat. Nos. 5,703,436 and 5,707,745, which are incorporated by reference in their entireties, disclose examples of cathodes including compound cathodes having a thin layer of metal such as Mg:Ag with an overlying transparent, electrically-conductive, sputter-deposited ITO layer. The theory and use of blocking layers is described in more detail in U.S. Pat. No. 6,097,147 and U.S. Patent Application Publication No. 2003/0230980, which are incorporated by reference in their entireties. Examples of injection layers are provided in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety. A description of protective layers may be found in U.S. Patent Application Publication No. 2004/0174116, which is incorporated by reference in its entirety.
The simple layered structure illustrated in
Structures and materials not specifically described may also be used, such as OLEDs comprised of polymeric materials (PLEDs) such as disclosed in U.S. Pat. No. 5,247,190 to Friend et al., which is incorporated by reference in its entirety. By way of further example, OLEDs having a single organic layer may be used. OLEDs may be stacked, for example as described in U.S. Pat. No. 5,707,745 to Forrest et al, which is incorporated by reference in its entirety. The OLED structure may deviate from the simple layered structure illustrated in
Unless otherwise specified, any of the layers of the various embodiments may be deposited by any suitable method. For the organic layers, preferred methods include thermal evaporation, ink-jet, such as described in U.S. Pat. Nos. 6,013,982 and 6,087,196, which are incorporated by reference in their entireties, organic vapor phase deposition (OVPD), such as described in U.S. Pat. No. 6,337,102 to Forrest et al., which is incorporated by reference in its entirety, and deposition by organic vapor jet printing (OVJP, also referred to as organic vapor jet deposition (OVJD)), such as described in U.S. Pat. No. 7,431,968, which is incorporated by reference in its entirety. Other suitable deposition methods include spin coating and other solution based processes. Solution based processes are preferably carried out in nitrogen or an inert atmosphere. For the other layers, preferred methods include thermal evaporation, sputtering, chemical vapor deposition, atomic layer deposition, and electron beam deposition. Preferred patterning methods include deposition through a mask, photolithography, and cold welding such as described in U.S. Pat. Nos. 6,294,398 and 6,468,819, which are incorporated by reference in their entireties, and patterning associated with some of the deposition methods such as ink-jet and organic vapor jet printing (OVJP). Other methods may also be used. The materials to be deposited may be modified to make them compatible with a particular deposition method. For example, substituents such as alkyl and aryl groups, branched or unbranched, and preferably containing at least 3 carbons, may be used in small molecules to enhance their ability to undergo solution processing. Substituents having 20 carbons or more may be used, and 3-20 carbons are a preferred range. Materials with asymmetric structures may have better solution processability than those having symmetric structures, because asymmetric materials may have a lower tendency to recrystallize. Dendrimer substituents may be used to enhance the ability of small molecules to undergo solution processing.
Devices fabricated in accordance with embodiments of the present disclosure may further optionally comprise a barrier layer. One purpose of the barrier layer is to protect the electrodes and organic layers from damaging exposure to harmful species in the environment including moisture, vapor and/or gases, etc. The barrier layer may be deposited over, under or next to a substrate, an electrode, or over any other parts of a device including an edge. The barrier layer may comprise a single layer, or multiple layers. The barrier layer may be formed by various known chemical vapor deposition techniques and may include compositions having a single phase as well as compositions having multiple phases. Any suitable material or combination of materials may be used for the barrier layer. The barrier layer may incorporate an inorganic or an organic compound or both. The preferred barrier layer comprises a plurality of alternative layers of polymeric material and non-polymeric material; organic material and inorganic material; or a mixture of a polymeric material and a non-polymeric material as one example described in U.S. Pat. No. 7,968,146, PCT Pat. Application Nos. PCT/US2007/023098 and PCT/US2009/042829, which are herein incorporated by reference in their entireties.
Devices fabricated in accordance with embodiments of the present disclosure can be incorporated into a wide variety of electronic component modules (or units) that can be incorporated into a variety of electronic products or intermediate components. Examples of such electronic products or intermediate components include display screens, lighting devices such as discrete light source devices or lighting panels, etc. that can be utilized by the end-user product manufacturers. Such electronic component modules can optionally include the driving electronics and/or power source(s). Devices fabricated in accordance with embodiments of the present disclosure can be incorporated into a wide variety of consumer products that have one or more of the electronic component modules (or units) incorporated therein. A consumer product comprising an OLED that includes the compound of the present disclosure in the organic layer in the OLED is disclosed. Such consumer products would include any kind of products that include one or more light source(s) and/or one or more of some type of visual displays. Some examples of such consumer products include flat panel displays, curved displays, computer monitors, medical monitors, televisions, billboards, lights for interior or exterior illumination and/or signaling, heads-up displays, fully or partially transparent displays, flexible displays, rollable displays, foldable displays, stretchable displays, laser printers, telephones, mobile phones, tablets, phablets, personal digital assistants (PDAs), wearable devices, laptop computers, digital cameras, camcorders, viewfinders, micro-displays (displays that are less than 2 inches diagonal), 3-D displays, virtual reality or augmented reality displays, vehicles, video walls comprising multiple displays tiled together, theater or stadium screen, a light therapy device, and a sign. Various control mechanisms may be used to control devices fabricated in accordance with the present disclosure, including passive matrix and active matrix. Many of the devices are intended for use in a temperature range comfortable to humans, such as 18 degrees C. to 30 degrees C., and more preferably at room temperature (20-25° C.), but could be used outside this temperature range, for example, from −40 degree C. to +80° C.
More details on OLEDs, and the definitions described above, can be found in U.S. Pat. No. 7,279,704, which is incorporated herein by reference in its entirety.
The materials and structures described herein may have applications in devices other than OLEDs. For example, other optoelectronic devices such as organic solar cells and organic photodetectors may employ the materials and structures. More generally, organic devices, such as organic transistors, may employ the materials and structures.
In some embodiments, the OLED has one or more characteristics selected from the group consisting of being flexible, being rollable, being foldable, being stretchable, and being curved. In some embodiments, the OLED is transparent or semi-transparent. In some embodiments, the OLED further comprises a layer comprising carbon nanotubes. In some embodiments, the OLED further comprises one or more quantum dots. Such quantum dots can be in the emissive layer, or in other functional layers, such as a down conversion layer.
In some embodiments, the OLED comprises a RGB pixel arrangement or white plus color filter pixel arrangement. In some embodiments, the OLED is a mobile device, a handheld device, or a wearable device. In some embodiments, the OLED is a display panel having less than 10 inch diagonal or 50 square inch area. In some embodiments, the OLED is a display panel having at least 10 inch diagonal or 50 square inch area. In some embodiments, the OLED is a lighting panel.
The materials described herein are as various examples useful for a particular layer in an OLED. They may also be used in combination with a wide variety of other materials present in the device. For example, emissive dopants disclosed herein may be used by themselves in the EML, or in conjunction with a wide variety of other emitters, hosts, transport layers, blocking layers, injection layers, electrodes and other layers that may be present. The materials described or referred to below are non-limiting examples of materials that may be useful in combination with the compounds and the devices disclosed herein, and one of skill in the art can readily consult the literature to identify other materials that may be useful in combination.
A charge transport layer can be doped with conductivity dopants to substantially alter its density of charge carriers, which will in turn alter its conductivity. The conductivity is increased by generating charge carriers in the matrix material, and depending on the type of dopant, a change in the Fermi level of the semiconductor may also be achieved. Hole-transporting layer can be doped by p-type conductivity dopants and n-type conductivity dopants are used in the electron-transporting layer. In some embodiments, conductivity dopants comprise at least one chemical moiety selected from the group consisting of cyano, fluorinated aryl or heteroaryl, fluorinated alkyl or cycloalkyl, alkylene, heteroaryl, amide, benzodithiophene, and highly conjugated heteroaryl groups extended by non-ring double bonds.
A hole injecting/transporting material to be used in the present disclosure is not particularly limited, and any compound may be used as long as the compound is typically used as a hole injecting/transporting material. Examples of the material include, but are not limited to: a phthalocyanine or porphyrin derivative; an aromatic amine derivative; an indolocarbazole derivative; a polymer containing fluorohydrocarbon; a polymer with conductivity dopants; a conducting polymer, such as PEDOT/PSS; a self-assembly monomer derived from compounds such as phosphonic acid and silane derivatives; a metal oxide derivative, such as MoOx; a p-type semiconducting organic compound, such as 1,4,5,8,9,12-Hexaazatriphenylenehexacarbonitrile; a metal complex, and a cross-linkable compounds.
Examples of aromatic amine derivatives used in HIL or HTL include, but not limit to the following general structures:
Each of Ar1 to Ar9 is selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, benzofuropyridine, furodipyridine, benzothienopyridine, thienodipyridine, benzoselenophenopyridine, and selenophenodipyridine; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Each of Ar1 to Ar9 may be unsubstituted or may be substituted by a general substituent as described above, any two substituents can be joined or fused into a ring.
In some embodiments, each Ar1 to Ar9 independently comprises a moiety selected from the group consisting of:
wherein k is an integer from 1 to 20; X101 to X108 is C or N; Z101 is C, N, O, or S.
Examples of metal complexes used in HIL or HTL include, but are not limited to the following general formula:
wherein Met is a metal, which can have an atomic weight greater than 40; (Y101-Y102) is a bidentate ligand, the coordinating atoms of Y101 and Y102 are independently selected from C, N, O, P, and S; L101 is an another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k″ is the maximum number of ligands that may be attached to the metal.
In some embodiments, (Y101-Y102) is a 2-phenylpyridine or 2-phenylimidazole derivative. In some embodiments, (Y101-Y102) is a carbene ligand. In some embodiments, Met is selected from Ir, Pt, Pd, Os, Cu, and Zn. In some embodiments, the metal complex has a smallest oxidation potential in solution vs. Fc+/Fc couple less than about 0.6 V.
In some embodiments, the HIL/HTL material is selected from the group consisting of phthalocyanine and porphyrin compounds, starburst triarylamines, CFx fluorohydrocarbon polymer, conducting polymers (e.g., PEDOT:PSS, polyaniline, polythiophene), phosphonic acid and silane SAMs, triarylamine or polythiophene polymers with conductivity dopants, Organic compounds with conductive inorganic compounds (such as molybdenum and tungsten oxides), n-type semiconducting organic complexes, metal organometallic complexes, cross-linkable compounds, polythiophene based polymers and copolymers, triarylamines, triaylamine with spirofluorene core, arylamine carbazole compounds, triarylamine with (di)benzothiophene/(di)benzofuran, indolocarbazoles, isoindole compounds, and metal carbene complexes.
An electron blocking layer (EBL) may be used to reduce the number of electrons and/or excitons that leave the emissive layer. The presence of such a blocking layer in a device may result in substantially higher efficiencies, and/or longer lifetime, as compared to a similar device lacking a blocking layer. Also, a blocking layer may be used to confine emission to a desired region of an OLED. In some embodiments, the EBL material has a higher LUMO (closer to the vacuum level) and/or higher triplet energy than one or more emitters closest to the EBL interface. In some embodiments, the compound used in EBL contains at least one carbazole group and/or at least one arylamine group. In some embodiments the HOMO level of the compound used in the EBL is shallower than the HOMO level of one or more of the hosts in the EML. In some embodiments, the compound used in EBL contains the same molecule or the same functional groups used as one of the hosts described herein.
The light emitting layer of the organic EL device of the present disclosure preferably contains at least a light emitting material as the dopant, and a host material. Examples of the host material are not particularly limited, and any metal complexes or organic compounds may be used as long as the host won't fully quench the emission of the dopant.
Examples of metal complexes used as host are preferred to have the following general formula:
wherein Met is a metal; (Y103-Y104) is a bidentate ligand, the coordinating atoms of Y103 and Y104 are independently selected from C, N, O, P, and S; L101 is an another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal; and k′+k″ is the maximum number of ligands that may be attached to the metal.
In some embodiments, the metal complexes are:
wherein (O—N) is a bidentate ligand, having metal coordinated to atoms O and N.
In some embodiments, Met is selected from Ir and Pt. In a further embodiment, (Y103-Y104) is a carbene ligand.
In some embodiments, the host compound contains at least one of the following groups selected from the group consisting of aromatic hydrocarbon cyclic compounds such as benzene, biphenyl, triphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene; the group consisting of aromatic heterocyclic compounds such as dibenzothiophene, dibenzofuran, dibenzoselenophene, furan, thiophene, benzofuran, benzothiophene, benzoselenophene, carbazole, indolocarbazole, pyridylindole, pyrrolodipyridine, pyrazole, imidazole, triazole, oxazole, thiazole, oxadiazole, oxatriazole, dioxazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine, oxazine, oxathiazine, oxadiazine, indole, benzimidazole, indazole, indoxazine, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine, pteridine, xanthene, acridine, phenazine, phenothiazine, phenoxazine, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-carbazole, aza-indolocarbazole, aza-triphenylene, aza-tetraphenylene, 5λ2-benzo[d]benzo[4,5]imidazo[3,2-a]imidazole, 5,9-dioxa-13b-boranaphtho[3,2,1-de]anthracene; and the group consisting of 2 to 10 cyclic structural units which are groups of the same type or different types selected from the aromatic hydrocarbon cyclic group and the aromatic heterocyclic group and are bonded to each other directly or via at least one of oxygen atom, nitrogen atom, sulfur atom, silicon atom, phosphorus atom, boron atom, chain structural unit and the aliphatic cyclic group. Each option within each group may be unsubstituted or may be substituted by the General Substituents as described herein or may be further fused.
In some embodiments, the host compound comprises at least one of the moieties selected from the group consisting of:
wherein k is an integer from 0 to 20 or 1 to 20. X101 to X108 are independently selected from C or N. Z101 and Z102 are independently selected from C, N, O, or S.
In some embodiments, the host material is selected from the group consisting of arylcarbazoles, metal 8-hydroxyquinolates, (e.g., alq3, balq), metal phenoxybenzothiazole compounds, conjugated oligomers and polymers (e.g., polyfluorene), aromatic fused rings, zinc complexes, chrysene based compounds, aryltriphenylene compounds, poly-fused heteroaryl compounds, donor acceptor type molecules, dibenzofuran/dibenzothiophene compounds, polymers (e.g., pvk), spirofluorene compounds, spirofluorene-carbazole compounds, indolocabazoles, 5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole), tetraphenylene complexes, metal phenoxypyridine compounds, metal coordination complexes (e.g., Zn, Al with N{circumflex over ( )}N ligands), dibenzothiophene/dibenzofuran-carbazole compounds, silicon/germanium aryl compounds, aryl benzoyl esters, carbazole linked by non-conjugated groups, aza-carbazole/dibenzofuran/dibenzothiophene compounds, and high triplet metal organometallic complexes (e.g., metal-carbene complexes).
One or more emitter materials may be used in conjunction with the compound or device of the present disclosure. The emitter material can be emissive or non-emissive in the current device as described herein. Examples of the emitter materials are not particularly limited, and any compounds may be used as long as the compounds are capable of producing emissions in a regular OLED device. Examples of suitable emitter materials include, but are not limited to, compounds which are capable of producing emissions via phosphorescence, non-delayed fluorescence, delayed fluorescence, especially the thermally activated delayed fluorescence, i.e., TADF (also referred to as E-type delayed fluorescence), triplet-triplet annihilation, or combinations of these processes.
In some embodiments, the emitter material has the formula of M(L1)x(L2)y(L3)z;
wherein each L2 and L3 are independently selected from the group consisting of
and the structures of LIGAND LIST; wherein:
In some embodiments, the emitter material is selected from the group consisting of the following Dopant Group 1:
In some embodiments, the emitter material is selected from the group consisting of the following Dopant Group 2:
In some embodiments of the above Dopant Groups 1 and 2, each unsubstituted aromatic carbon atom can be replaced with N to form an aza-ring. In some embodiments, the maximum number of N atom in one ring is 1 or 2. In some embodiments of the above Dopant Groups 2, Pt atom in each formula can be replaced by Pd atom.
In some embodiments of the OLED, the delayed fluorescence material comprises at least one donor group and at least one acceptor group. In some embodiments, the delayed fluorescence material is a metal complex. In some embodiments, the delayed fluorescence material is a non-metal complex. In some embodiments, the delayed fluorescence material is a Zn, Cu, Ag, or Au complex.
In some embodiments of the OLED, the delayed fluorescence material has the formula of M(L5)(L6), wherein M is Cu, Ag, or Au, L5 and L6 are different, and L5 and L6 are independently selected from the group consisting of:
In some embodiments of the OLED, the delayed fluorescence material comprises at least one of the donor moieties selected from the group consisting of:
wherein YT, YU, YV, and YW are each independently selected from the group consisting of B, C, Si, Ge, N, P, O, S, Se, C═O, S═O, and SO2.
In some of the above embodiments, any carbon ring atoms up to maximum of a total number of three, together with their substituents, in each phenyl ring of any of above structures can be replaced with N.
In some embodiments, the delayed fluorescence material comprises at least one of the acceptor moieties selected from the group consisting of nitrile, isonitrile, borane, fluoride, pyridine, pyrimidine, pyrazine, triazine, aza-carbazole, aza-dibenzothiophene, aza-dibenzofuran, aza-dibenzoselenophene, aza-triphenylene, imidazole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, triazole, thiadiazole, and oxadiazole. In some embodiments, the acceptor moieties and the donor moieties as described herein can be connected directly, through a conjugated linker, or a non-conjugated linker, such as a sp3 carbon or silicon atom.
In some embodiments, the fluorescent material comprises at least one of the chemical moieties selected from the group consisting of:
wherein YF, YG, YH, and YI are each independently selected from the group consisting of B, C Si, Ge, N, P, O, S, Se, C═O, S═O, and SO2;
In some of the above embodiments, any carbon ring atoms up to maximum of a total number of three, together with their substituents, in each phenyl ring of any of above structures can be replaced with N.
A hole blocking layer (HBL) may be used to reduce the number of holes and/or excitons that leave the emissive layer. The presence of such a blocking layer in a device may result in substantially higher efficiencies and/or longer lifetime as compared to a similar device lacking a blocking layer. Also, a blocking layer may be used to confine emission to a desired region of an OLED. In some embodiments, the HBL material has a lower HOMO (further away from the vacuum level) and/or higher triplet energy than one or more of the emitters closest to the HBL interface.
In some embodiments, a compound used in the HBL contains the same molecule or the same functional groups used as host described above.
In some embodiments, a compound used in the HBL comprises at least one of the following moieties selected from the group consisting of:
wherein k is an integer from 1 to 20; L101 is another ligand, k′ is an integer from 1 to 3.
Electron transport layer (ETL) may include a material capable of transporting electrons. Electron transport layer may be intrinsic (undoped), or doped. Doping may be used to enhance conductivity. Examples of the ETL material are not particularly limited, and any metal complexes or organic compounds may be used as long as they are typically used to transport electrons.
In some embodiments, compound used in ETL comprises at least one of the following moieties in the molecule:
and fullerenes; wherein k is an integer from 1 to 20, X101 to X108 is selected from C or N; Z101 is selected from the group consisting of C, N, O, and S.
In some embodiments, the metal complexes used in ETL contains, but not limit to the following general formula:
wherein (O—N) or (N—N) is a bidentate ligand, having metal coordinated to atoms O, N or N, N; L101 is another ligand; k′ is an integer value from 1 to the maximum number of ligands that may be attached to the metal.
In some embodiments, the ETL material is selected from the group consisting of anthracene-benzoimidazole compounds, aza triphenylene derivatives, anthracene-benzothiazole compounds, metal 8-hydroxyquinolates, metal hydroxybenoquinolates, bathocuproine compounds, 5-member ring electron deficient heterocycles (e.g., triazole, oxadiazole, imidazole, benzoimidazole), silole compounds, arylborane compounds, fluorinated aromatic compounds, fullerene (e.g., C60), triazine complexes, and Zn (N{circumflex over ( )}N) complexes.
In tandem or stacked OLEDs, the CGL plays an essential role in the performance, which is composed of an n-doped layer and a p-doped layer for injection of electrons and holes, respectively. Electrons and holes are supplied from the CGL and electrodes. The consumed electrons and holes in the CGL are refilled by the electrons and holes injected from the cathode and anode, respectively; then, the bipolar currents reach a steady state gradually. Typical CGL materials include n and p conductivity dopants used in the transport layers.
In any compounds disclosed herein, the hydrogen atoms can be partially or fully deuterated. The minimum amount of hydrogen of the compound being deuterated is selected from the group consisting of 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, and 100%. As used herein, percent deuteration has its ordinary meaning and includes the percent of all possible hydrogen and deuterium atoms that are replaced by deuterium atoms. In some embodiments, the deuterium atoms are attached to an aromatic ring. In some embodiments, the deuterium atoms are attached to a saturated carbon atom, such as an alkyl or cycloalkyl carbon atom. In some other embodiments, the deuterium atoms are attached to a heteroatom, such as Si, or Ge atom.
It is understood that the various embodiments described herein are by way of example only and are not intended to limit the scope of the invention. For example, many of the materials and structures described herein may be substituted with other materials and structures without deviating from the spirit of the invention. The present invention as claimed may therefore include variations from the particular examples and preferred embodiments described herein, as will be apparent to one of skill in the art. It is understood that various theories as to why the invention works are not intended to be limiting.
A 500 mL 4-neck flask, equipped with a stir bar, condenser, thermocouple, and nitrogen inlet, was charged with 4-(tert-butyl)-2-chloropyridine (4.6 g, 27.1 mmol, 1.0 equiv), 4,4,5,5-tetramethyl-2-(5,5,8,8-tetrakis(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,3,4,6,6,7,7-d7)-1,3,2-dioxaborolane 1 (20.8 g, 62.4 mmol, 2.3 equiv), tribasic potassium phosphate monohydrate (17.3 g, 81.3 mmol, 3.0 equiv), toluene (193 mL) and ethanol (32 mL). The mixture was sparged 10 minutes with nitrogen. (Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl) [2-(2′-amino-1,1′-biphenyl)]palladium (II)) (XPhosPdG2) (0.43 g, 0.54 mmol, 0.02 equiv) was added then the reaction mixture was heated overnight at reflux (˜87° C.). The reaction mixture was cooled to room temperature, concentrated, and the residue was combined with the residue of a previous run (2.95 mmol scale). A solution of the crude material in dichloromethane (300 mL) was filtered through a pad of Celite® (diatomaceous earth)(40 g), rinsing with dichloromethane (20 mL) and ethyl acetate (2×40 mL). The filtrate was washed with water (100 mL) then absorbed onto Celite® (30 g). The adsorbed material was purified on a Biotage automated purification system (350 g HC Biotage silica gel cartridge), eluting with 1-15% ethyl acetate in hexanes, to give 4-(tert-butyl)-2-(5,5,8,8-tetrakis(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,3,4,6,6,7,7-d7)pyridine 2 (8.9 g, 87% yield), containing residual hexanes, as a colorless oil.
A 250 mL 3-neck flask, equipped with a stir bar, condenser, thermocouple, and nitrogen inlet, was charged with 4-(tert-butyl)-2-(5,5,8,8-tetrakis(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,4,6,6,7,7-d)-pyridine (2) (6.8 g, 20.0 mmol, 2.1 equiv), 2-ethoxyethanol (70 mL) and DIUF water (18 mL). The reaction mixture was sparged 15 minutes with nitrogen. Iridium (III) chloride hydrate (3.0 g, 9.48 mmol, 1.0 equiv) was added to the reaction mixture, then the reaction mixture was heated 4 days at reflux. The reaction mixture was cooled to room temperature, filtered, and the solid washed with methanol (30 mL). The solid was vacuum dried 6 hours at 60° C. to give di-μ-chloro-tetrakis-[κ2(C2,N)-(4-(tert-butyl)-(2-(5,5,8,8-tetrakis(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,4,6,6,7,7-d6)-3′-yl)pyridin-1-yl]diiridium(III) 3 (6.94 g, 80% yield, 98% LCMS purity, 82% 1H-NMR purity) as a yellow solid.
A 250 mL round bottom flask, fitted with a stir bar, septum, and nitrogen inlet, was charged with di-μ-chloro-tetrakis[κ2(C2,N)-(4-(tert-butyl)-(2-(5,5,8,8-tetrakis(methyl-d)-5,6,7,8-tetrahydronaphthalen-2-yl-1,4,6,6,7,7-d6)-3′-yl)pyridin-1-yl]diiridium(III) 3(4.6 g, 2.54 mmol, 1.0 equiv), dichloromethane (40 mL) and methanol (10 mL). The reaction mixture was sparged 5 minutes with nitrogen. Silver trifluoromethanesulfonate (1.44 g, 5.59 mmol, 2.2 equiv) was added to the reaction mixture. Then the flask was wrapped with foil to exclude light, then the reaction mixture was stirred 18 hours at room temperature. The reaction mixture was filtered through a pad of Celite® (35 g) topped with silica gel (25 g), rinsing with dichloromethane (850 mL) and the filtrate concentrated under reduced pressure. The solid was vacuum dried at 55° C. to give [Ir(4-(tert-butyl)-(2-(5,5,8,8-tetrakis-(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,4,6,6,7,7-d6)-3′-yl)pyridin-1-yl)-(1H))2(MeOH)2]trifluoromethanesulfonate 4 (4.91 g, 89% yield, 96% LCMS purity) as a yellow solid.
A 500 mL 4-neck round bottom flask, equipped with a stirrer, reflux condenser, and thermocouple, was charged with [Ir(4-(tert-butyl)-(2-(5,5,8,8-tetrakis(methyl-d3)-5,6,7,8-tetrahydronaphthalen-2-yl-1,4,6,6,7,7-d6)-3′-yl)pyridin-1-yl)(1H))2(MeOH)2]trifluoromethanesulfonate 4 (6.71 g, 6.20 mmol, 1.1 equiv), 4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)-2-(phenanthro[3,2-b]benzofuran-11-yl)pyridine 5 (2.45 g, 5.64 mmol, 1.0 equiv) and acetone (190 mL). The reaction mixture was sparged 10 minutes with nitrogen. Triethylamine (2.4 mL, 16.91 mmol, 3.0 equiv) was added to the reaction mixture, then the reaction mixture was heated 60 hours at reflux under an inert atmosphere. The reaction mixture was then subjected to photolysis to yield the crude reaction mixture. The crude reaction mixture was concentrated under reduced pressure. The residue was subjected to column chromatography to give Inventive compound 1(2.67 g, 36% yield, 99.9% UPLC purity) as a yellow solid.
n-BuLi (1.6 M, 1.2 eq, 139.0 mL, 222.4 mmol) was added dropwise (within about 25 mins) at −78° C. (dry ice acetone bath temperature) to a solution of 6-bromo-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (49.52 g, 1 eq, 185.30 mmol) in anhydrous THF (220 mL). The reaction mixture was allowed to stir at −78° C. for 1 hour. Trimethyl borate (31 mL, 1.5 eq, 278.0 mmol) was then added. The reaction mixture was allowed to warm to room temperature slowly and stirred for another 2 hours. 2 N HCl (300 mL) was slowly added. The reaction mixture was extracted with EtOAc (3×50 mL) and dried with MgSO4. After filtration, the filtrate was condensed under rotavapor to give the product 1′ as a yellowish oil, which solidified upon standing (39.5 g, 92% yield)
2-bromo-4-methoxybenzaldehyde (34.7 g, 1 eq, 161.4 mmol), (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronic acid 1 (41.2 g, 1.1 eq, 177.5 mmol), Sphos-Pd-G2 (2.33 g, 0.02 eq, 3.23 mmol), and K3PO4 (68.5 g, 2 eq, 322.7 mmol) were added to a 500 mL round bottom flask. Then, 1,4-dioxane (240 mL) and H2O (50 mL) were added, and the headspace of the flask was flushed with N2 for 10 mins. The reaction mixture was then heated under N2 at 95° C. (oil bath temperature) overnight. After cooling down to room temperature, NH4Cl (sat. aq. sol, 100 mL) was added. The resulting organic layer was separated, the aqueous layer was extracted with CH2Cl2 (3×100 mL) and dried with MgSO4. After condensing under vacuum, the residue was purified on silica gel using CH2Cl2/heptane (7/3) to give the desired compound 2′ as a white solid (48.15 g, 93% yield, 99.7% LCMS purity)
tBuOK (34.88 g, 2 eq, 310.9 mmol) at 0° C. (ice water bath temperature) was added to a solution of Wittig salt (90.58 g, 1.7 eq, 264.2 mmol) in anhydrous THF (700 mL). The reaction mixture was stirred for 2 hours at 0° C., and then 4-methoxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzaldehyde 2 (50.12 g, 1 eq, 155.4 mmol) in THF (190 mL) was added at 0° C. The reaction mixture was then stirred at room temperature for 3 hours. TLC (thin layer chromatography) showed a complete formation of the desired product. Then the reaction mixture was quenched with H2O (500 mL) and extracted with CH2Cl2 (4×100 mL). After drying with MgSO4 and evaporation of solvents, the residue was purified on silica gel using CH2Cl2/heptanes (3/7) to give the desired product 3′ as a yellowish oil (49.85 g, 92% yield)
AlCl3 (28.44 g, 1.5 eq, 213.3 mmol) was added to a solution of 6-(5-methoxy-2-(2-methoxyvinyl)phenyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 3 (49.85 g, 1 eq, 142.2 mmol) in 1,2-dichloroethane (500 mL) portion wise at room temperature. The reaction mixture was stirred at room temperature for 5 hours. When TLC showed completion of the reaction, the mixture was filtered through Celite and washed with CH2Cl2 (3×50 mL). After removal of the solvents under vacuum, the residue was purified on silica gel using CH2Cl2/heptanes (1/4), to give 4′ as a yellowish oil (25.38 g, 56% yield)
A solution of 2-methoxy-8,8,11,11-tetramethyl-8,9,10,11-tetrahydrotetraphene 4 (21.83 g, 1 eq, 68.55 mmol) in anhydrous THF (200 mL) was cooled to −78° C. (dry ice acetone bath temperature). n-BuLi (2.5 M in hexane, 1.8 eq, 49.4 mL, 123.4 mmol) was added dropwise (within about 15 mins) at −78° C. and the reaction mixture was warmed up to room temperature, stirred for 4 hours. The reaction mixture was then cooled down to −78° C., 1,2-dibromoethane (13.6 mL, 2.3 eq, 157.7 mmol) was added dropwise (within about 10 mins) and continued stirring at −78° C. for 30 mins before warming up to room temperature and stirring for 1 hour. The reaction mixture was quenched with NH4Cl (sat. aq, sol., 100 mL) and extracted with CH2Cl2 (3×30 mL). After drying with MgSO4 and evaporation of solvents, the residue was purified on silica gel using CH2Cl2/heptane (1/9) to give the desired product 5′ as a yellowish solid (23.88 g, 88% yield).
3-bromo-2-methoxy-8,8,11,11-tetramethyl-8,9,10,11-tetrahydrotetraphene 5 (23.88 g, 1 eq, 60.10 mmol), (3-chloro-2-fluorophenyl)boronic acid (13.62 g, 1.3 eq, 78.13 mmol), Sphos-Pd-G2 (2.16 g, 0.05 eq, 3.00 mmol), and K3PO4 (25.51 g, 2 eq, 120.19 mmol) were added to a 500 mL round bottom flask. Then, 1,4-doxane (300 mL) and H2O (80 mL) were added, and the headspace of the flask was flushed with N2 for 10 mins. The reaction mixture was then heated under N2 at 90° C. (oil bath temperature) overnight. After cooling down to room temperature, NH4Cl (sat. aq. sol, 100 mL) was added. The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (3×30 mL) and dried with MgSO4. After condensing under vacuum, the residue was purified on silica gel using CH2Cl2/heptane (18%/82%) to give the desired compound 6′ as a white solid (24.18 g, 90% yield, 99% LCMS purity).
BBr3 (12.8 mL, 2.5 eq, 135.2 mmol) was added dropwise to a solution of 3-(3-chloro-2-fluorophenyl)-2-methoxy-8,8,11,11-tetramethyl-8,9,10,11-tetrahydrotetraphene 6 (24.18 g, 1 eq, 54.10 mmol) in CH2Cl2 (300 mL) at 0° C. (ice water bath temperature), and stirred at 0° C. for 30 mins. The reaction mixture was then warmed up to room temperature and continued stirring for 4 hours. MeOH (50 mL) was added slowly at 0° C. (ice water bath), the mixture was extracted with CH2Cl2 (3×40 mL) and dried with MgSO4. After evaporation of the solvents, the residue was purified on silica gel using CH2Cl2/heptane (3/2), which gave the desired product 7′ as a white solid (21.85 g, 93% yield).
A representative procedure: K2CO3 (20.92 g, 3.0 eq, 151.4 mmol) was added to a 500 mL round bottom flask, containing a solution of 3-(3-chloro-2-fluorophenyl)-8,8,11,11-tetramethyl-8,9,10,11-tetrahydrotetraphen-2-ol 7 (21.85 g, 1 eq, 50.47 mmol) in DMF (200 mL). The headspace of the flask was flushed with N2 for 5 minutes. The reaction mixture was then heated under N2 at 120° C. (oil bath temperature) overnight. After cooling down to room temperature, NH4Cl (sat. aq. sol, 100 mL) and EtOAc (100 mL) were added, and the mixture was stirred for 20 minutes. The organic layer was separated, the aqueous layer was extracted with CH2Cl2 (10×30 mL), EtOAc (5×30 mL), and dried with MgSO4. After condensing under vacuum, the residue was purified on silica gel using CH2Cl2/heptane (15%/85%) to give the desired compound 8′ as a white solid (18.58 g, 89% yield)
In a 500 mL 4-neck flask, fitted with a stir bar, condenser and thermocouple, 12-chloro-1,1,4,4-tetramethyl-1,2,3,4-tetrahydrotetrapheno[2,3 b]benzofuran (6.20 g, 1.0 equiv, 15.01 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (17.16 g, 4.5 equiv, 67.6 mmol) and potassium acetate (4.42 g, 3.0 eq, 45.04 mmol) were suspended in 1,4-dioxane (140.0 mL) and the mixture sparged with nitrogen for 5 minutes. Dicyclohexyl(2′,6′-dimethoxy-[1,1′-biphenyl]-2-yl) phosphane (493.1 mg, 0.08 equiv, 1.20 mmol) and tris(dibenzylideneacetone)dipalladium (0) (412.5 mg, 0.03 equiv, 450.4 μmol) were added and the reaction mixture heated at vigorous reflux for 4 hours. Solvent was evaporated to yield crude mixture of compound 9′. The crude mixture was used for the next step without further purification.
The crude reaction mixture containing 9 was treated with DI water (28 mL; pre-sparged with nitrogen) and stirred for 10 minutes where upon 2-chloro-4-(2,2-dimethylpropyl-1,1-d2)-5-(methyl-d3)pyridine (3.04 g, 1.0 equiv, 15.01 mmol), potassium phosphate tribasic (4.78 g, 1.5 equiv, 22.52 mmol) were added and the mixture was sparged with nitrogen for additional 5 minutes. Tetrakis triphenylphosphine palladium (0) (0.35 g, 0.02 equiv, 300.2 μmol) was added and the reaction mixture was heated at reflux for 18 hours. The reaction mixture was concentrated, the residue diluted with DCM (500 mL) and washed with water (2×150 mL). The organic layer was filtered using filter paper and the filtrate was concentrated and subjected to column chromatography to yield 10′. (6.05 g, 11.11 mmol, 74% yield).
A 250 mL 4-neck flask fitted with a stir bar, condenser, nitrogen inlet, and thermocouple was charged with compound 10 (3.1 g, 5.690 mmol), [Ir(4-(tert-butyl)-(2-phenyl-2′-yl)pyridin-1-yl)(−1H))2(MeOH)2]trifluoromethanesulfonate 11(4.33 g, 1.0 equiv) and acetone (130 mL). The suspension was sparged with nitrogen. Triethylamine (2.4 mL, 3.0 equiv) was added and heated at 51° C. overnight. After 20 hours, the reaction mixture was allowed to cool down and then concentrated. The residue was diluted in dichloromethane (60 mL) and passed through a pad of Celite (50 g). The Celite layer was washed with dichloromethane until all yellow color was removed (60 mL). The filtrate was concentrated and redissolved in dichloromethane (30 mL). Methanol was added (˜150 mL) and the solution partially concentrated in a rotary evaporator until a thick slurry was formed. The solids were filtered off, and air dried to deliver crude reaction mixture. Then the reaction mixture was subjected to photolysis to yield the desired product. (3.10 g, 2.68 mmol, 99.907%, 47% yield) as a bright yellow solid.
All example devices were fabricated by high vacuum (<10−7 Torr) thermal evaporation. The anode electrode was 800 Å of indium tin oxide (ITO). The cathode consisted of 10 Å of Liq (8-hydroxyquinoline lithium) followed by 1,000 Å of Al. All devices were encapsulated with a glass lid sealed with an epoxy resin in a nitrogen glove box (<1 ppm of H2O and O2) immediately after fabrication with a moisture getter incorporated inside the package. The organic stack of the device examples consisted of sequentially, from the ITO Surface: 100 Å of HAT-CN as the hole injection layer (HIL); 400 Å of HTM as a hole transporting layer (HTL); emissive layer (EML) with thickness 400 Å. Emissive layer containing H-host (H1): E-host (H2) in 6:4 ratio and 12 weight % of green emitter. 350 Å of Liq (8-hydroxyquinoline lithium) doped with 35% of ETM as the ETL. Device structure is shown in Table 1. Table 1 shows the schematic device structure. The chemical structures of the materials used in the test devices are shown below.
Upon fabrication, the devices were measured for EL, JVL, and lifetested at DC 80 mA/cm2. Device performance data is shown in Table 2.
The above data shows that the Inventive compound 1 exhibited higher EQE (10% higher at 10 mA/cm2) and higher luminous efficacy (11% higher at 10 mA/cm2) than Comparative compound 1. Those numbers are beyond any value that could be attributed to experimental error and the observed improvements are significant and unexpected. Without being bound by any particular theory, it is presumed that this particular cycloalkyl chain modification on a dopant structure may increase performance of an OLED device.
This application is a continuation-in-part of U.S. patent application Ser. No. 18/814,301, filed on Aug. 23, 2024, the entire contents of which are incorporated herein by reference. This application also claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Applications No. 63/664,204, filed on Jun. 26, 2024, No. 63/562,444, filed on Mar. 7, 2024, No. 63/625,704, filed on Jan. 26, 2024, No. 63/620,548, filed on Jan. 12, 2024, and No. 63/614,955, filed on Dec. 27, 2023, the entire contents of which are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 63614955 | Dec 2023 | US | |
| 63625704 | Jan 2024 | US | |
| 63620548 | Jan 2024 | US | |
| 63562444 | Mar 2024 | US | |
| 63664204 | Jun 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 18814301 | Aug 2024 | US |
| Child | 18985455 | US |
